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November 9-10, 2009 
 
PREFACE 
 
Dear Colleagues,  
 
 Welcome to the FSHD International Research Consortium 2009. Thanks to you, we are seeing 
numerous developments in every aspect of FSHD basic and clinical research!  We hope that this 
meeting will allow us to define the complex mechanism and various features of FSHD and enable us to 
move quickly to the development of potential treatments for FSH muscular dystrophy.   
 
This past year has brought with it quite a significant increase in government, non-profit, and 
private funding for FSHD.  It has also ushered in an international collaboration of volunteer health 
agencies and FSHD patients working side-by-side with research and clinical communities.  It is 
essential for the entire community to work together at every level and to communicate clearly on 
programs, developments and needs. 
 
 This year’s workshop participants include clinicians, scientists, biotechnology companies, 
pharmaceutical companies, government and non-profit funding agencies, along with patients – 
committed to solving, treating and curing FSHD at this workshop.  More than 75 people have 
registered for this workshop making this the “place to be” for anyone with a keen interest in FSHD.  At 
the second day, we will hold a round table discussion to discuss the future needs of FSHD.  We hope 
for a thoughtful and productive morning in which all FSHD issues will be openly discussed to direct us 
towards a new and better future for patients suffering with FSHD.  
 
 This meeting is organized and sponsored by the FSH Society, the U.S. DHHS NIH Eunice 
Kennedy Shriver NICHD Sen. Paul D. Wellstone BBRI FSHD Muscular Dystrophy Cooperative 
Research Center, the Association Française Contre les Myopathies (AFM), the Muscular Dystrophy 
Association (MDAUSA), FSHD Global Research Foundation, Fields Center for FSHD and 
Neuromuscular Research, Acceleron Pharma, Genzyme, Genomic Vision, and Athena Diagnostics.  It 
is truly a pleasure to bring the entire group together to accelerate solutions for facioscapulohumeral 
muscular dystrophy!   
  
 Thank you for coming.  Thank you for sharing.  Thank you for your extraordinary efforts and 
hard work on behalf of patients and their families.   
 
Daniel Paul Perez 
FSH Society, Inc., Watertown, Massachusetts, USA 
 
Kathryn Wagner, M.D., Ph.D. 
Kennedy Krieger Institute, Baltimore, Maryland  USA  
The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 
 
Silvère van der Maarel, Ph.D. 
Leiden University Medical Center, Leiden, the Netherlands 
 
The FSH Society, Inc. (Facioscapulohumeral Muscular Dystrophy) is an independent, non-profit 501(c)(3) and tax-exempt 
U.S. corporation organized to address issues and needs specifically related to facioscapulohumeral muscular dystrophy 
(FSHD). Contributions and financial donations are acknowledged for tax purposes.  All inquiries should be addressed to: 
FSH Society, Inc., Daniel Paul Perez, 11 Elmbrook Circle, Bedford, Massachusetts 01730 USA.   Phone: (781) 275-7781, 
fax: (781) 275-7789, e-mail: daniel.perez@fshsociety.org, website: http://www.fshsociety.org  
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Day 1 
 
Monday, November 9, 2009 
 
 
Registration &  
       Continental Breakfast  7:30-8:00 
 
 
Welcome    8:00-8:30 
 
Session 1    8:30-9:30 SNPs & Diagnosis (3x20 minutes) 
 
Session 2    9:30-10:30 Chromatin (3x20 minutes) 
 
Break & Poster viewing  10:30-11:00 
 
Session 3    11:00-12:20 Biomarkers & Genotype Phenotype (4x20 minutes) 
 
Lunch & Poster viewing  12:20-13:50 
 
Session 4    13:50-14:50 Model Systems (3x20 minutes) 
 
Session 5    14:50-15:50 DUX4 (3x20 minutes) 
 
Break & Poster viewing  15:50-16:20 (moderators prepare for plenary session) 
 
Session 6    16:20-17:40 FRG1 & CRYM (4x20 minutes) 
 
Conclude    17:40-18:00 
 
 
Dinner at Henrietta’s Table   19:00-22:00 Private Dining Room, Charles Hotel, Harvard Square 
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Day 2 
 
Tuesday, November 10, 2009 
 
 
Continental Breakfast  7:30-8:00 
 
 
Welcome &    8:00-8:05 
   Charge to the Body   
      Co-Chairs:   
Kathryn Wagner, M.D., Ph.D. 
 Kennedy Krieger Institute, Baltimore, Maryland  USA & 
 The Johns Hopkins University School of Medicine, Baltimore, Maryland  USA  & 
Silvère van der Maarel, Ph.D. 
 Leiden University Medical Center, Leiden, the Netherlands 
 
Review    8:05-8:20 Review of significant insights November 9 
   Co-Chairs:   
Kathryn Wagner, M.D., Ph.D. & Silvère van der Maarel, Ph.D. 
 
    8:20-8:30 Recap FSH Society 2006 Tactical & Strategic Plan  
   Facilitators:  Rune R. Frants, Ph.D., Leiden University Medical Center, the Netherlands & 
              Michael R. Altherr, Ph.D., Los Alamos National Laboratory, New Mexico 
 
      Outline available online at FSH Society, Inc.:  
      http://www.fshsociety.org/pages/resPSocPlan.html    
 
Session 1   8:30-9:15 Scope of FSHD Research 
 Facilitators:  Kathryn Wagner, M.D., Ph.D. & Rune R. Frants, Ph.D.   
 Discussion by entire Group 
 
 Suggested topics:  
 Clinical Research: potential drugs, and important outcome measures, Critical experiments that need to 
 be redone, corroborated, Epigenetics, Chromatin, Nuclear localization/signals, SNPs, Chromosome 
 folding, Imprinting, and Genomic sequence 
  
Session 2   9:15-10:15 Assumptions on which solving FSHD rests 
 Facilitators:  Silvère van der Maarel, Ph.D. & Michael R. Altherr, Ph.D. 
 Discussion by entire Group 
 
 
Session 3   10:15-11:15 Requirements for solving FSHD 
 3 Breakout Sessions:  
       1.  Clinical Research:  potential drugs, and important outcome measures  
                             Facilitators:  Kathryn Wagner, M.D., Ph.D. &  Rabi Tawil, M.D. & 
                       John Porter, Ph.D., NIH NINDS 
       2.  Molecular genetics:  epigenetics, chromatin, genomics    
       Facilitators:  Silvere van der Maarel & Lou Kunkel, Ph.D. &  
            Ljubisa Vitkovic, Ph.D., NIH Eunice Kennedy Shriver NICHD           
       3.  Cell biology:  cells,  mouse, stem cells research 
                  Facilitators:  Davide Gabellini, Ph.D. & Leslie Lock, Ph.D. & 
                                  Glen Nuckolls, Ph.D., NIH NIAMS  
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Break & Lunch  11:15-11:45 
 
Session 4   11:45-13:30 Tasks included and needing to be accomplished 
 Facilitators:  Michael R. Altherr, Ph.D. & Rune R. Frants, Ph.D.   
 Discussion by entire Group 
 
Session 5   13:30-14:00 Cost estimates, time and schedule 
 Facilitators:  Silvère van der Maarel, Ph.D.  & Kathryn Wagner, M.D., Ph.D 
 Discussion by entire Group 
 
Conclude   14:00 
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   First Author  Presenting Author Session 
 
 
8:30-8:50 a.m.   Tsumagari  Ehrlich   SNPs and Diagnosis 
8:50-9:10 a.m.   Lemmers  Lemmers  SNPs and Diagnosis 
9:10-9:30 a.m.  Sacconi   Sacconi   SNPs and Diagnosis 
 
9:30-9:50 a.m.   Cabianca  Cabianca  Chromatin 
9:50-10{10 a.m.   Ma   Ehrlich   Chromatin 
10:10-10:30 a.m.   Zeng   Yokomori  Chromatin 
 
10:30-11:00 a.m.        Posters & Break 
 
11:00-11:20 a.m.   Fitzsimons  Fitzsimons   Biomarkers & Genotype Phenotype 
11:20-11:40 a.m.   Rahimov  Wagner/J.B. Miller Biomarkers & Genotype Phenotype 
11:40-12:00 p.m.  de Greef   Tawil    Biomarkers & Genotype Phenotype 
12:00-12:20 p.m.  Rahimov  Wagner   Biomarkers & Genotype Phenotype 
 
12:20-1:50 p.m.        Posters & Lunch 
 
1:50-2:10 p.m.   Krom   Butler-Browne  Model systems 
2:10-2:30 p.m.   Kyba   Kyba   Model systems 
2:30-2:50 p.m.   Block   D.G. Miller  Model systems 
 
2:50-3:10 p.m.   Tassin   Tassin   DUX4 
3:10-3:30 p.m.   Wallace   Wallace   DUX4 
3:30-3:50 p.m.   Knopp   Zammit   DUX4 
 
3:50-4:20 p.m.        Posters & Break 
 
4:20-4:40 p.m.   Liu   Liu   FRG1 and CRYM 
4:40-5:00 p.m.   Wuebbles  Long   FRG1 and CRYM 
5:00-5:20 p.m.   Reed   Reed   FRG1 and CRYM 
5:20-5:40 p.m.   Sun   Sun   FRG1 and CRYM 
 
 
Posters 
 
[   Borgstein   Borgstein  Poster  
   Corona   Rosa   Poster 
   Dmitriev  Dmitriev  Poster 
   Ehrlich   Ehrlich   Poster 
   Hampson  Hampson  Poster 
10:30-11:50 a.m.    Hanel   Jones    Poster 
    &   Knopp   Knopp   Poster  
12:20-1:50 p.m  Lachey   Lachey   Poster  
   &   Lunt   Lunt    Poster 
3:50-4:20 p.m.  Nguyen   Walrafen  Poster 
   Reed   Bloch   Poster 
   Ricci    Ricci   Poster 
   Sacconi   Sacconi   Poster 
   Stadler   Stadler   Poster 
  ] Tupler   Tupler   Poster 
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7:30-8:00 a.m. 
REGISTRATION & CONTINENTAL BREAKFAST  
 
 
8:00-8:10 a.m. 
WELCOME 
 
Daniel Paul Perez  
President & CEO, FSH Society, Watertown, Massachusetts  USA 
 
Charles P. Emerson, Jr., Ph.D. 
Boston Biomedical Research Institute, Watertown, Massachusetts  USA  & 
U.S. NIH Eunice Kennedy Shriver NICHD Boston Biomedical Research Institute Senator Paul D. 
Wellstone Muscular Dystrophy Cooperative Research Center 
 
 
8:10-8:30 a.m. 
CO-CHAIRS OPENING REMARKS &  
CHARGE TO THE MEETING ATTENDEES 
 
Kathryn Wagner, M.D., Ph.D. 
Kennedy Krieger Institute, Baltimore, Maryland  USA & 
The Johns Hopkins University School of Medicine, Baltimore, Maryland  USA 
 
Silvère van der Maarel, Ph.D. 
Leiden University Medical Center, Leiden, the Netherlands 
 
 
8:30 a.m.-9:30 a.m. 
PLATFORM PRESENTATIONS I  
Rabi Tawil, M.D., Moderator 
Neuromuscular Disease Center, University of Rochester Medical Center & 
Fields Center for FSHD and Neuromuscular Research, Rochester, New York  USA 
 
 
SNPs & DIAGNOSIS  
 
8:30-8:50 a.m.  
Melanie Ehrlich, Ph.D. 
Human Genetics Program and the Department of Biochemistry, Tulane Medical School, New Orleans, 
Louisianna 70112 USA 
 
An easy test for the presence of the 4qA161 FSHD-permissive haplotype and its 
application to studying the molecular genetics of FSHD 
Koji Tsumagari1, Desheng Chen1, Aaron D. Bossler2, and Melanie Ehrlich1 
1 Human Genetics Program and the Department of Biochemistry, Tulane Medical School, New Orleans, 
Louisianna 70112 USA 
2 Molecular Pathology Laboratory, University of Iowa Hospitals and Clinic, Iowa City Iowa 52242 USA 
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8:50-9:10 a.m.  
Richard J.L.F. Lemmers, Ph.D. 
Department of Human Genetics, Leiden University Medical Center, The Netherlands 
 
 The evolution of the subtelomeres of chromosomes 4q and 10q 
 Richard JLF Lemmers, Patrick van der Vliet, Kristiaan J van der Gaag, Sofia Zuniga, Rune R Frants, Peter de 
 Knijff, Silvère M. van der Maarel 
 Department of Human Genetics, Leiden University Medical Center, The Netherlands 
 
9:10-9:30 a.m.  
Sabrina Sacconi, Ph.D. 
Centre de référence des maladies Neuromusculaires, CHU,  Nice, France 
 
High frequency of hypomethylation in patients with FSHD like phenotype 
S Sacconi 1, JC de Greef 2, RJLF Lemmers2, P Camano3, SM van der Maarel 2  & C Desnuelle1 
1
 Centre de référence des maladies Neuromusculaires, CHU,  Nice, France 
2
 Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The  
    Netherlands 
3
 Neuroscience Unit, Biodonostia Institute, San Sebastián, Spain 
 
 
9:30 a.m.-10:30 a.m. 
PLATFORM PRESENTATIONS II    
Jane E. Hewitt, Ph.D., Moderator 
Institute of Genetics, School of Biology, University of Nottingham, Queen’s Medical Centre, 
Nottingham, NG7 2UH, United Kingdom 
 
CHROMATIN  
 
9:30-9:50 a.m. 
Daphne Cabianca, M.S. 
Division of Regenerative Medicine, San Raffaele Scientific Institute, Milano, Italy 
Dulbecco Telethon Institute, Milano, Italy 
 
A ncRNA regulates chromatin conformation of the facioscapulohumeral muscular 
dystrophy region. 
Daphne Cabianca1,2, Beatrice Bodega3, Victoria Neguembor1, Enrico Ginelli3 and Davide Gabellini1,4 
1
 Division of Regenerative Medicine, San Raffaele Scientific Institute, Milano, Italy 
2
 UniSR-Open University International PhD Program in Cellular and Molecular Biology, Milano, Italy 
3
 Department of Biology and Genetics for Medical Sciences, University of Milano, Italy 
4
 Dulbecco Telethon Institute, Milano, Italy 
 
9:50-10:10 a.m. 
Melanie Ehrlich, Ph.D. 
Human Genetics Program and the Department of Biochemistry, Tulane Medical School, New Orleans, 
Louisiana 70112 USA  
 
Chromatin modification at DNaseI hypersensitive sites in 4q35 in myoblasts 
Jing-Jing Ma1, Shao-Chi Chang1, Xueqing Xu1, Dmitri Loukinov2, Victor Lobanenkov2, and Melanie Ehrlich1 
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1Human Genetics Program and the Department of Biochemistry, Tulane Medical School, New Orleans, Louisiana 
70112 USA  
2Molecular Pathology Section, National Institute of Allergy and Infectious Diseases, Rockville, Maryland  20852 
USA 
 
10:10-10:30 a.m. 
Kyoko Yokomori, D.V.M., Ph.D. 
Department of Biological Chemistry, School of Medicine, University of California, Irvine, California  
USA  
 
Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at 
D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD) 
Weihua Zeng, 1 Jessica C. de Greef, 2 Yen-Yun Chen, 1 Richard Chien, 1 Xiangduo Kong, 1 Heather C. Gregson, 1 
Sara T. Winokur, 1 April Pyle, 3 Keith D. Robertson, 4 John A. Schmiesing, 1 Virginia E. Kimonis, 5 Judit Balog, 2 
Rune R. Frants, 2 Alexander R. Ball, Jr., 1 Leslie F. Lock, 1 Peter J. Donovan, 1 Silvère M. van der Maarel, 2 and 
Kyoko Yokomori1 
1 Department of Biological Chemistry, School of Medicine, University of California, Irvine, California 92697-
1700  USA  
2 Leiden University Medical Center, Center for Human and Clinical Genetics, P.O. Box 9600, 2300 RC Leiden, 
The Netherlands 
3 Institute for Stem Cell Biology and Medicine, Department of Microbiology, Immunology and Molecular 
Genetics, David Geffen School of Medicine at UCLA, 277A BSRB Box 951489, Los Angeles, California 90095-
1489  USA 
4 Department of Biochemistry and Molecular Biology, University of Florida, Box 100245, Gainesville, Florida 
32610  USA4;  
5 Division of Medical Genetics and Metabolism, Department of Pediatrics, University of California Irvine Medical 
Center, 101 The City Drive South, ZC4482, Orange California 92868  USA 
 
 
10:30 a.m.-11:00 a.m. 
POSTER VIEWING & MORNING BREAK  
[FOR LISTING OF THE POSTERS PLEASE SEE LUNCH PROGRAM] 
 
 
11:00 a.m.-12:20 p.m. 
PLATFORM PRESENTATIONS III   
Michael Kyba, Ph.D., Moderator 
Lillehei Heart Institute and Department of Pediatrics, University of Minnesota, Minneapolis, 
Minnesota USA 
 
BIOMARKERS & GENOTYPE/PHENOTYPE 
 
11:00-11:20 p.m. 
Robin B. Fitzsimons, M.B., B.S., B.Sc., (Med), Ph.D., FRACP 
University of Sydney, Sydney, NSW, 2000  Australia 
 
FSHD and signal patterns in retina and muscle:  Can  twentieth century embryology help 
‘decode’   twenty-first century molecular enigmas?   
Robin B. Fitzsimons, M.B., B.S., B.Sc., (Med), Ph.D., FRACP 
University of Sydney, Sydney, NSW, 2000  Australia 
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11:20-11:40 p.m. 
Jeffrey Boone Miller, Ph.D. 
Boston Biomedical Research Institute, Watertown, Massachusetts USA & 
NIH Eunice Kennedy Shriver NICHD BBRI Senator Paul D. Wellstone Muscular Dystrophy 
Cooperative Research Center for FSHD Research  
 
FSHD biomarker studies:  Using micro-qPCR arrays to analyze gene expression in FSHD 
and control muscle biopsies and myogenic cell cultures. 
Fedik Rahimov1, 2, Jennifer Chen2, 3, Vivek K. Vishnudas2, 3, Kendal Hanger2, 3, Oliver King2, 3, Jeffrey B. Miller2, 
3
, Kathryn Wagner2, 4, Louis M. Kunkel1, 2, and Charles P. Emerson2, 3.  
1
 Children's Hospital Boston, 300 Longwood Avenue, Boston, Massachusetts 02115 USA 
2
 NIH Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center for FSHD Research  
3
 Boston Biomedical Research Institute, 64 Grove Street, Watertown, Massachusetts 02472 USA 
4
 The Kennedy Krieger Institute & The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205  
USA 
 
11:40 a.m.-12:00 p.m.  
Rabi Tawil, M.D. 
Neuromuscular Disease Center, University of Rochester Medical Center, Rochester, New York   USA 
 
Genotype-phenotype studies in FSHD2 
JC de Greef1, RJLF Lemmers1, RR Frants1, SM van der Maarel1, R Tawil2 
1Department of Human Genetics, Leiden University Medical Center, The Netherlands 
2Neuromuscular Disease Center, University of Rochester Medical Center, USA 
 
12:00-12:20 p.m. 
Kathryn Wagner, M.D., Ph.D. 
The Kennedy Krieger Institute & The Johns Hopkins University School of Medicine, Baltimore, 
Maryland 21205  USA 
 
Biomarkers of Myostatin Inhibition for Future Trials in FSHD 
Fedik Rahimov1, 3, Oliver King3, 4, Louis M. Kunkel1, 2, 3, Kathryn R. Wagner3, 5, 6  
1
 Program in Genomics and 2Howard Hughes Medical Institute, Children’s Hospital Boston, Harvard Medical 
School, Boston,  Massachusetts 02115 USA 
3
 NIH Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center for FSHD Research  
4
 Boston Biomedical Research Institute, 64 Watertown, Massachusetts 02472 USA 
5
 The Kennedy Krieger Institute and 6The Johns Hopkins University School of Medicine, Baltimore, Maryland 
21205 USA 
 
 
12:20 p.m.-1:50 p.m. 
BUFFET LUNCH & POSTER VIEWING  
 
Presenting: Niels Borgstein, M.D. 
Acceleron Pharma, Cambridge, Massachusetts USA 
Initial results from single subcutaneous administration of ACE-031, a form of the soluble 
activin type IIB receptor, in healthy postmenopausal volunteers 
Borgstein N.G*., Yang Y.*, Condon C.H.*, Wilson D.M.*, Haltom E.*, Larouche R. #, Lachey J.L.*, Seehra J.*, 
Sherman M.L.*  
*Acceleron Pharma, Cambridge, Massachusetts, USA; #Anapharm, Montreal, Canada 
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Presenting: Alberto Luis Rosa, M.D., Ph.D. 
Laboratorio de Biología Celular y Molecular, Fundación Allende, Córdoba, Argentina 
Subcellular trafficking of DUX4, a pro-apoptotic protein encoded at the 
facioscapulohumeral muscular dystrophy locus FSHD1A 
Edgardo Daniel Corona and Alberto Luis Rosa 
Laboratorio de Biología Celular y Molecular, Fundación Allende, Hipólito Irigoyen 384 / 8vo Piso – 5000 - 
Córdoba, Argentina 
 
Presenting: Petr Dmitriev, Ph.D. 
UMR 8126, Université Paris-Sud 11, CNRS, Institut de Cancérologie Gustave-Roussy, Villejuif, 
France 
Krüppel-like factor KLF15 Interacts with the D4Z4 enhancer and up regulates the 
FSHD-related gene DUX4c 
Petr Dmitriev1, Andrei Petrov#,1 , Eugenie Ansseau#,3, Sébastien Charron#,3, Frédérique Coppée3,  Alexandra 
Belayew3, Gilles Carnac2, Ahmed Turki2, Dalila Laoudj2, Marc Lipinski1 and Yegor S. Vassetzky1 
1
 UMR 8126, Université Paris-Sud 11, CNRS, Institut de Cancérologie Gustave-Roussy, F-94804 Villejuif, France 
2
 INSERM EA 4202 ERI25, 371 Avenue du Doyen Gaston Giraud  F-34295 Montpellier, France 
3 Service de Biologie Moléculaire, Université de Mons-Hainaut; 6, avenue du champ de Mars, 7000, Mons, 
Belgium 
 
Presenting: Melanie Ehrlich, Ph.D. 
Human Genetics Program and the Department of Biochemistry, Tulane Medical School, New Orleans, 
Louisiana 70112 USA 
A Window into secrets of myogenesis genes: whole-genome DNaseI hypersensitivity 
mapping  
Melanie Ehrlich1, Koji Tsumagari1, L. Song2, T. S. Fuery2, D. London2, A. P. Boyle2, G. E. Crawford2 
1 Human Genetics Program and the Department of Biochemistry, Tulane Medical School, New Orleans, Louisiana 
70112 USA 
2 Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina 27708  USA 
 
Presenting: Amanda Hampson, Ph.D. 
Institute of Genetics, School of Biology, Queen’s Medical Centre, University of Nottingham, 
Nottingham, NG7 2UH  United Kingdom 
Studying sequence variation at the human D4Z4 and mouse DUX loci 
Amanda Hampson, Laura M Mitchell, Gemma Dennis, Andreas Leidenroth, Joanne Pollinton and Jane E Hewitt.  
Institute of Genetics, School of Biology, Queen’s Medical Centre, University of Nottingham, Nottingham, NG7 
2UH  United Kingdom 
 
Presenting: Peter L. Jones, Ph.D. 
Department of Cell and Developmental Biology; University of Illinois at Urbana-Champaign, Urbana, 
Illinois  USA 
Endogenous FRG1 protein expression in human and mouse skeletal muscle 
`Meredith L. Hanel, Jessica Chia-Yun Sun, and Peter L. Jones 
Department of Cell and Developmental Biology; University of Illinois at Urbana-Champaign; 601 S. Goodwin 
Ave, B107 Chemical and Life Sciences Laboratory; Urbana, Illinois 61801 USA 
 
Presenting: Jennifer Lachey, Ph.D. 
Acceleron Pharma, Cambridge, Massachusetts USA 
Long-term activin receptor type IIB inhibition improves strength and function of 
dystrophic muscle 
Lachey, J.L., Bogdanovich, S., Pistilli, E.E., Pullen, A.E., Khurana, T., Seehra, J. 
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Acceleron Pharma Cambridge, Massahuseetts 02139  USA 
University of Pennsylvania and Pennsylvania Muscle Institute, Philadelphia Pennsylvania 19104  USA 
 
Presenting: Peter Lunt, Ph.D. 
Clinical Genetics Dept, St Michaels Hospital, Bristol BS2 8EG  United Kingdom 
Experience in use of 4qA and 4qB in diagnostic testing for FSHD 
Peter Lunt1, Suzanne O’Shea2, Gemma Dennis2, Anne Gardner2 ,Maggie Williams2 
1 Clinical Genetics Dept, St Michaels Hospital, Bristol BS2 8EG  United Kingdom 
2 Bristol Genetics Laboratories, Southmead Hospital, Bristol BS10 5NB  United Kingdom 
 
Presenting: Pierre Walrafen, Ph.D. 
Genomic Vision, Paris  France. 
Transferring the Molecular Combing test for FSHD in a routine diagnostics lab: lessons 
learned and new findings 
Pierre Walrafen1, Karine Nguyen,2,3 Catherine Vovan2 , Anne Vannier1 , Emilie Renard1, Charlène Chaix1, 
Rafaëlle Bernard2,3, Aaron Bensimon1 ,Nicolas Lévy2,3 
1
 Genomic Vision, Paris Santé Cochin, 29 rue du Faubourg Saint Jacques, 75014 Paris  France. 
2
 Département de Génétique Médicale, Hôpital d'enfants Timone, 265 rue St Pierre, Marseille  France. 
3 Inserm UMR_S910 "Génétique Médicale et Génomique Fonctionnelle", Université de la Méditerranée, Faculté 
de Médecine, 27, Bd Jean Moulin, Marseille  France. 
4These authors contributed equally to this work 
 
Presenting: Patrick Reed, Ph.D. 
University of Maryland School of Medicine, Baltimore, Maryland  USA   
NIH Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center for FSHD 
Research  
Toward quantitative proteomic comparisons of skeletal muscles from FSHD patients and their 
unaffected, first-degree relatives 
Patrick W. Reed1,2, Kathryn Wagner2.3, and Robert J. Bloch1,2 
1
 University of Maryland School of Medicine, Baltimore, Maryland  USA   
2
 NIH Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center for FSHD Research  
3 The Kennedy Krieger Institute & The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205  
USA 
 
Presenting: Enzo Ricci, M.D. 
Istituti di Neurologia e di Radiologia Università Cattolica -Policlinico Gemelli – Roma 
Pelvic and lower limb involvement in FSHD: a muscle MRI study 
Ricci E., Frusciante R., Tasca G., Iannaccone E., Monforte M., Renna R., Silvestri G., Mirabella M., Pelliccioni 
M., Padua L.,  Pescatori M., Di Lella G., La Schena F., Ottaviani P., Tonali P.A.  
Istituti di Neurologia e di Radiologia Università Cattolica -Policlinico Gemelli – Roma 
Radiologia –Istituto Dermopatico dell'Immacolata IRCCS - Roma 
 
Presenting: Sabrina Sacconi, Ph.D. 
Centre de Référence des Maladies Neuromusculaires, Hôpital Archet 1, Nice, France 
Electrostimulation training: an effective and safe treatment for FSHD patients 
Sabrina Sacconi1, Serge S. Colson2, Michaël Benchortane1, Véronique Tanant1, Claude Desnuelle1 
1
 Centre de Référence des Maladies Neuromusculaires, Hôpital Archet 1, Nice, France 
2
 Laboratoire de Motricité Humaine, Education, Santé, University of Nice-Sophia Antipolis 
 
Presenting: Guido Stadler, Ph.D. 
Department of Cell Biology, UT Southwestern Medical Center at Dallas, Dallas, Texas  USA  
NIH Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center for FSHD 
Establishment of clonal myogenic cell lines from severely affected dystrophic muscles – 
tools for studying FSHD 
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Guido Stadler1,4, Jennifer Chen2,4, Charles Emerson2,4, Kathryn Wagner3,4, Jerry Shay1, Woodring Wright1,4 
1 Department of Cell Biology, UT Southwestern Medical Center at Dallas, Dallas, Texas  USA  
2 Boston Biomedical Research Institute, Watertown, Massachusetts  USA  
3 Center for Inherited Muscle Disorders, The Kennedy Krieger Institute, Baltimore, Maryland  USA 
4 NIH Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center for FSHD 
 
Presenting: Rossella Tupler, M.D., Ph.D. 
Dipartimento di Scienze Biomediche, Universita’ di Modena e Reggio Emilia, Modena, Italia 
Program in Gene Function and Expression, University of Massachusetts Medical School, Worcester, 
Massachusetts USA 
Unexpected high percentage of subjects carrying D4Z4 reduced alleles and no clinical 
signs in FSHD families: which factors contribute to the disease mechanism? 
Emanuela Bonifazi1, Costanza Lamperti2, Chiara Fiorillo3, Liliana Vercelli4, Carlo Borsato5, Roberto Frusciante6, 
Maura Servida2, Francesca Greco1, Ilaria Frambolli1, Luca Colantoni7, Giulia Ricci8, Leda Volpi8, Rita Di Leo9, 
Claudia Manzoli10, Paola Cudia11, Ebe Pastorello5, Leopoldo Ricciardi10, Monica Govi1, Isabella Scionti1, 
Michelangelo Cao5, Gabriele Siciliano8, Giuliana Galluzzi7, Morandi Lucia11, Di Muzio Antonio10, Trevisan Carlo 
Pietro5, Enzo Ricci6, Carmelo Rodolico9, Lucio Santoro3, Giuliano Tomelleri12, Corrado Angelini5, Laura 
Palmucci4, Maurizio Moggio2, Rossella Tupler1, 13. 
1Dipartimento di Scienze Biomediche, Università di Modena e Reggio Emilia, Via G. Campi 287, 41100 Modena. 
Tel. +39 059 2055414 - Fax +39 059 205 5426 – e-mail: rossella.tupler@unimore.it 2UO Neurologia, Fondazione 
Ospedale Maggiore Policlinico, Mangiagalli Regina Elena, IRCCS Milano. 3Dipartimento di Scienze 
Neurologiche, Università Federico II, Napoli. 4Dipartimento di Neuroscienze, Università di Torino. 5Dipartimento 
di Neuroscienze, Università di Padova. 6Dipartimento di Neuroscienze, Università Cattolica Policlinico Agostino 
Gemelli, Roma. 7Genetica molecolare, IRCCS Fondazione Santa Lucia, Roma. 8Dipartimento di Neuroscienze, 
Università di Pisa. 9Dipartimento di Neuroscienze, Psichiatria ed Anestesiologia, Università di Messina. 
10Dipartimento di Medicina e Scienze dell'invecchiamento, Osp. Civ. "SS Annunziata", Chieti. 11 Malattie 
Neuromuscolari, Neurologia, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milano, 12 Dipartimento di 
Scienze Neurologiche e della Visione, Università di Verona, 13 Program in Gene Function and Expression, 
University of Massachusetts Medical School, Worcester, USA 
 
 
1:50 p.m.-2:50 p.m. 
PLATFORM PRESENTATIONS IV  
Charles P. Emerson, Jr., Ph.D., Moderator 
Boston Biomedical Research Institute, Watertown, Massachusetts  USA  & 
U.S. NIH Eunice Kennedy Shriver NICHD Boston Biomedical Research Institute Senator Paul D. 
Wellstone Muscular Dystrophy Cooperative Research Center 
 
 
MODEL SYSTEMS 
 
1:50-2:10 p.m. 
Gillian Butler-Browne, Ph.D. 
Institute of Myology, UMRS 974 - UPMC University of Paris, Inserm, Paris, France 
 
Isogenic immortalized myoblasts clones with or without mutation 
Yvonne Krom1, Kammel Machmaoui2, Bianca den Hamer1, Baziel van Engelen3, Vincent Mouly2, Rune Frants1, 
Rabi Tawil4, Gillian Butler-Browne2, Silvere van der Maarel1 
1 Department of Human Genetics, Leiden University Medical Center, Netherlands 
2 Institute of Myology, UMRS 974 - UPMC Univ. Paris 6 / U974 - Inserm / UMR7215 – CNRS, France 
3 Department of Neurology, Radboud University Nijmegen Medical Center, Netherlands 
4 Department of Neurology, University of Rochester Medical Center, Rochester, New York 
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2:10-2:30 p.m. 
Michael Kyba, Ph.D. 
Lillehei Heart Institute and Department of Pediatrics, University of Minnesota, Minneapolis, 
Minnesota USA 
 
Investigating disease mechanisms and cell therapy with pluripotent cells bearing FSHD 
mutations 
Michael Kyba1, Darko Bosnakovski1, Abhijit Dandapat1, Radbod Darabi3, John Day2, Jessica C. de Greef4, Lynn 
M. Hartweck1, Antonio Filareto3, Richard J. Lemmers4, Ramiro Nandez1, Rita R. Perlingeiro3, Janet Sowden4, 
Matthew Struck1, Rabi Tawil5, Silvere M. van der Maarel4, Nathan Zaidman1, and Thomas P Zwaka6 
1Lillehei Heart Institute and Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455 
USA 
2Paul and Sheila Wellstone Center for Muscular Dystrophy and Department of Neurology, University of 
Minnesota, Minneapolis, Minnesota 55455 USA 
3Lillehei Heart Institute and Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455 
USA 
4Department of Human Genetics, Leiden University Medical Center, Lund, The Netherlands 
5Fields Center for FSHD and Neuromuscular Research and Department of Neurology, University of Rochester, 
Rochester, New York 14642  USA 
6Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030 USA 
 
2:30-2:50 p.m. 
Daniel G. Miller, M.D., Ph.D. 
Department of Pediatrics, University of Washington, Seattle  USA 
 
Human and mouse developmental models of DUX4 transcriptional regulation 
Gregory J. Block1*, Chrissie Cirovic1*, Lisa M. Petek1*, Angel Nelson2*, Carol Ware 2*, Gala Fillipova3, Silvere 
van der Maarel4, Stephen J. Tapscott3, Daniel G. Miller1* 
1
 Department of Pediatrics, University of Washington, Seattle  USA 
2
 Department of Comparative Medicine, University of Washington, Seattle  USA 
3
 Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle  USA 
4
 Leiden University Medical Center, Leiden, The Netherlands. 
*
 Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle  USA 
 
 
2:50 p.m.-3:50 p.m. 
PLATFORM PRESENTATIONS V  
Jane E. Hewitt, Ph.D., Moderator 
Institute of Genetics, School of Biology, University of Nottingham, Queen’s Medical Centre, 
Nottingham, NG7 2UH, United Kingdom 
 
DUX4  
 
2:50-3:10 p.m. 
AlexandraTassin, Ph.D, 
Laboratory of Molecular Biology, University of Mons, Belgium 
 
Investigations on the molecular mechanism of FSHD by proteomic and metabonomic 
analyses of primary myotube cultures 
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A. Tassin1, B. Leroy2, S. Sauvage1, J. Faille1, V. Erculisse2, S. Charron1, C. Vanderplanck1, M. Barro5, L. Vander 
Elst3, RN. Muller3, D. Laoudj-Chenivesse5, JM. Colet4, F. Coppée1,R. Wattiez2, and A. Belayew1. 
Laboratories of:  1 Molecular Biology, 2 Proteomics and Protein Biochemistry, 3 NMR and Molecular Imaging, and 
4
 Human Biology and Toxicology, University of Mons, Belgium 
5
 Unité INSERM ERI 13, University of Montpellier, France.  
 
3:10-3:30 p.m. 
Lindsay Wallace, Ph.D. 
Department of Pediatrics, The Ohio State University, Columbus, Ohio 43205  USA 
Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, 
Ohio 43205  USA 
Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio  
USA 
 
DUX4 promotes FSHD-associated pathology in vivo 
Lindsay Wallace2, Sara Garwick3, Wenyan Mei, Frederique Coppee5, Alexandra Belayew5, Jing Yang and Scott Q. 
Harper1,2,3 
1Department of Pediatrics, The Ohio State University, Columbus, Ohio 43205  USA 
2Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, Ohio 43205  
USA 
3Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio 43205  
USA 
5Laboratoire de Biologie Moléculaire, Université de Mons-Hainaut, Académie Universitaire Wallonie-Bruxelles, 
Mons, Belgium 
 
3:30-3:50 p.m. 
Peter S. Zammit, Ph.D. 
King's College London, Randall Division of Cell and Molecular Biophysics, New Hunt's House, Guy's 
Campus, London, SE1 1UL, United Kingdom. 
 
Assessing the effects of FRG1, DUX4 and DUX4c on muscle satellite cell function 
Paul Knopp and Peter S. Zammit  
King's College London, Randall Division of Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, 
London, SE1 1UL, United Kingdom. 
 
 
 
3:50 p.m.-4:20 p.m. 
POSTER VIEWING & AFTERNOON BREAK  
[FOR LISTING OF THE POSTERS PLEASE SEE LUNCH PROGRAM] 
 
 
4:20-5:40 p.m. 
PLATFORM PRESENTATIONS VI  
Rune R. Frants, Ph.D., Moderator 
Leiden University Medical Center, Leiden, The Netherlands 
 
FRG1 & CRYM 
 
4:20-4:40 p.m. 
Qian Liu, Ph.D. 
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Department of Cell and Developmental Biology; University of Illinois at Urbana-Champaign, Urbana, 
Illinois  USA 
 
Facioscapulohumeral muscular dystrophy region gene-1 (FRG-1) is an actin bundling protein 
associated with muscle attachment sites 
Qian Liu, Takako Iida Jones, Vivian W. Tang, William M. Brieher, and Peter L. Jones 
Department of Cell and Developmental Biology; University of Illinois at Urbana-Champaign; 601 S. Goodwin Ave, 
B107 Chemical and Life Sciences Laboratory; Urbana, Illinois 61801 USA 
 
4:40-5:00 p.m. 
Steven W. Long, Ph.D. 
Department of Cell and Developmental Biology; University of Illinois at Urbana-Champaign, Urbana, 
Illinois  USA 
 
The effects of elevated FSHD candidate gene expression on vertebrate development using 
Xenopus laevis 
Ryan D. Wuebbles1,2, Steven W. Long1, Meredith L. Hanel, and Peter L. Jones 
Department of Cell and Developmental Biology; University of Illinois at Urbana-Champaign; 601 S. Goodwin 
Ave, B107 CLSL; Urbana Illinois 61801 USA 
 
5:00-5:20 p.m. 
Patrick Wayne Reed, Ph.D. 
University of Maryland School of Medicine, Baltimore, Maryland  USA   
 
Mu-Crystallin and the Pathogenesis of FSHD 
Patrick W. Reed and Robert J. Bloch 
University of Maryland School of Medicine, Baltimore, Maryland USA  
 
5:20-5:40 p.m. 
Jessica Chia-Yun Sun, Ph.D. 
Department of Cell and Developmental Biology; University of Illinois at Urbana-Champaign, Urbana, 
Illinois  USA 
 
Human FRG1 is a cytoplasmic actin bundling protein and a nuclear RNA associated 
protein 
Jessica Chia-Yun Sun, Michel Bellini, William M. Brieher, and Peter L. Jones 
Department of Cell and Developmental Biology; University of Illinois at Urbana-Champaign; 601 S. Goodwin 
Ave, B107 Chemical and Life Sciences Laboratory;Urbana, Illinois 61801 USA 
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1. 
 
An easy test for the presence of the 4qA161 FSHD-permissive haplotype and its application to 
studying the molecular genetics of FSHD 
 
Koji Tsumagari1, Desheng Chen1, Aaron D. Bossler2, and Melanie Ehrlich1 
 
1 Human Genetics Program and the Department of Biochemistry, Tulane Medical School, New 
Orleans, Louisianna 70112 USA 
2 Molecular Pathology Laboratory, University of Iowa Hospitals and Clinic, Iowa City Iowa 52242 
USA 
 
The identification of all the cis-acting elements at 4q35.2 that are necessary for pathogenesis in 
facioscapulohumeral muscular dystrophy (FSHD) is still uncertain. In all FSHD patients (~85) that 
were part of a recent study, Lemmers et al. (Am. J. Hum. Genet.:81, 884, 2007) found at least one 
copy of a haplotype, called 4qA161, that encompasses 4q35.2 sequences immediately proximal to 
D4Z4, distal to D4Z4, and at the first repeat unit of D4Z4. However, the 4qA161 haplotype is also 
present in ~60% of control individuals, and so can be referred to as FSHD-permissive. It should either 
contribute directly to pathogenesis or be linked to a polymorphism directly necessary for pathogenesis. 
Lemmers et al. mapped the frequency of the 4qA161 haplotype by the following procedure: 
1. determination of the D4Z4-distal A or B type in Southern blotting analysis after pulsed field 
gel electrophoresis (PFGE) using A-type and B-type oligonucleotide probes; 
2. and isolation of allelic 4q D4Z4 region bands by preparative PFGE on EcoRI digests blot-
hybridized to a p13E-11 probe, amplification of the extracted DNA by PCR, and analysis of the 
product for a simple sequence-length polymorphism ~3 kb proximal to D4Z4 by capillary gel 
electrophoresis.  
These procedures are time-consuming, and the harvesting of PFGE bands is challenging and too 
complicated for most clinical labs. Using sequence data from Lemmers et al., we designed a restriction 
endonuclease-PCR method based upon single nucleotide polymorphisms (SNPs) to determine if a 
sample has one, two, or no 4qA161 alleles by a procedure that eliminates the signal from 10q alleles. 
We found no 4qA161 haplotype in ~30% of 20 controls and none of 20 PFGE-confirmed FSHD 
patients represented in Tulane’s collection of DNA samples. From our Iowa collection of 15 FSHD 
samples, several had no 4qA161 haplotype but these samples had only been molecularly diagnosed by 
linear gel electrophoresis and Southern blotting with the p13E-11 as well as hybridization to D4Z4-
distal A and B probes and the BlnI resistance test for the most proximal repeat unit. Therefore, it is 
likely that our PCR SNP test helps to clarify the identification of FSHD-associated alleles, especially 
when 4qA hybridization to an allele with a short D4Z4 array occurs in the absence of p13E-11 
hybridization to this allele. The PCR products that we obtained from this assay are suitable for direct 
DNA sequencing. Initial sequencing results confirm the validity of our test and easily provide 
sequence information about the 4q D4Z4-proximal sub-region. Our method will aid clinicians in ruling 
out some false-positive FSHD patients, in prenatal screening, and in detecting rare patients with FSHD 
but without this haplotype. Our SNP test also has ramifications that can facilitate molecular genetic 
research on FSHD. (Funded in part by NIH grant R01 NS048859 to ME) 
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2. 
 
The evolution of the subtelomeres of chromosomes 4q and 10q 
 
Richard J.L.F. Lemmers, Patrick van der Vliet, Kristiaan J. van der Gaag, Sofia Zuniga, Rune R.R. 
Frants, Peter de Knijff, Silvère M. van der Maarel 
 
Department of Human Genetics, Leiden University Medical Center, the Netherlands 
 
 Subtelomeres are hot spots of inter- and intrachromosomal segmental duplications. 
Consequently, human subtelomeres are composed of blocks of homologous DNA sequences, called 
duplicons, which are dispersed over many different chromosome ends.  
FSHD is caused by the contraction of the macrosatellite repeat D4Z4 on the subtelomere of 
chromosome 4q35. We studied the human 4q and 10q subtelomeres, which contain the FSHD locus 
and which are identical over a region of on average >200 kb. Detailed sequence analysis of four 
polymorphic markers on 4q and 10q subtelomeres among samples from the African, European, and 
Asian HAPMAP panels revealed eighteen distinct 4q haplotypes and eight distinct 10q haplotypes. 
Haplotypes that were composed of D4Z4 repeat sequences that were otherwise specific for 4q and 10q 
were detected at frequencies >10% in all three populations, at first sight supporting a mechanism of 
and ongoing interchromosomal exchanges between chromosomes 4 and 10. 
 Further analysis allowed us to construct an evolutionary network of all haplotypes and to 
identify the 4q haplotype ancestral to all 4q and 10q haplotypes. Based on this network, we 
demonstrate that all haplotypes originate from only four discrete duplication events during recent 
human evolution. We also provide evidence that haplotypes with mixtures of 4q and 10q specific 
D4Z4 sequences (hybrid repeats) represent intermediate haplotypes in the transition from 4q to 10q 
haplotypes, rather than being the result of recent and recurrent translocations between both 
chromosomes. Haplotype distribution studies on a large number of globally dispersed human DNA 
samples (the HGDP-CEPH panel) supported our findings and show that all standard and non-standard 
haplotypes were already present in Africa before modern human migration out of Africa. Thus 
contrary to the earlier view of unconstrained exchanges between the of subtelomeric regions of 
chromosome 4 and 10, our studies suggest that only a few translocations have occurred between both 
chromosomes and that most probably intrachromosomal mutations explain the large number of 
standard and non-standard haplotypes. 
 
 Funding: This study was funded by the Fields Center, the Netherlands Organization for 
Scientific Research (NWO), the FSH Society and by the Prinses Beatrix Fonds. The authors declare no 
conflict of interest.  
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3. 
 
High frequency of hypomethylation in patients with FSHD like phenotype 
 
S. Sacconi 1, J.C. de Greef 2, R.J.L.F. Lemmers2, P. Camano3, S.M. van der Maarel 2  & C Desnuelle1 
 
1
 Centre de référence des maladies Neuromusculaires, CHU,  Nice, France 
2
 Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The  
    Netherlands 
3
 Neuroscience Unit, Biodonostia Institute, San Sebastián, Spain 
 
 We studied 9 sporadic patients presenting with typical FSHD clinical phenotype and absence of 
D4Z4 deletion on chromosome 4q35 tested by classical Southern blot technique.   
Clinical features included facial and shoulder girdle muscle weakness in association or not with pelvic, 
abdominal, and anterior forelegs muscle involvement. Muscle biopsies showed variable degree of 
muscular dystrophy, absence of abnormalities of cytoskeletal proteins routinely analyzed by 
immunohistochemistry and Western Blot. 
 We performed calpain 3 and valosin containing protein (VCP) mutation analysis by direct 
sequencing, extensive D4Z4 genotyping by PFGE analysis and DNA methylation studies of the D4Z4 
repeat.  
 We found 2 patients presenting with already known calpain 3 mutations, 1 patient presenting 
with a VCP mutation, 1 patient carrying a deletion of the probe region used for FSHD diagnosis, 1 
patient with a pathogenic complex rearrangement and 3 patients presenting with D4Z4 
hypomethylation.  For 1 out of 10 patients molecular diagnosis is still lacking. 
 We conclude that 1) even in absence of calpain3 deficiency detected by Western blot, this 
diagnosis has to be considered in patients with symmetric limb girdle muscular dystrophy and facial 
involvement, as well as the VCP diagnosis 2) PFGE analysis has to be performed routinely in FSHD 
diagnostic workout to exclude deletion of the probe region (alternatively these deletions can be 
detected by re-hybridizations with probe D4Z4) and more complex genetic rearrangements related to 
FSHD, and 3) the percentage of patients presenting with hypomethylation of D4Z4 not associated with 
D4Z4 deletion is very high and further studies are needed to better define this condition. We will 
provide a clinical and histological description of these 5 cases and a short discussion on features that 
they have in common.  
 
Keywords:  FSHD, Hypomethylation, Calpain 3, VCP 
 
Presenting author: 
 
Sabrina SACCONI 
Centre de référence des maladies Neuromusculaires 
Hôpital Archet 1 
06202 NICE, France 
E-mail: sacconi@unice.fr 
Telephone: +33 492 03 57 57 
Fax:  +33 492 03 58 91 
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4.  
 
A ncRNA regulates chromatin conformation of the facioscapulohumeral muscular dystrophy 
region. 
 
Daphne Cabianca1,2, Beatrice Bodega3, Victoria Neguembor1, Enrico Ginelli3 and Davide Gabellini1,4. 
 
1
 Division of Regenerative Medicine, San Raffaele Scientific Institute, Milano, Italy 
2
 UniSR-Open University International PhD Program in Cellular and Molecular Biology, Milano, Italy 
3
 Department of Biology and Genetics for Medical Sciences, University of Milano, Italy 
4
 Dulbecco Telethon Institute, Milano, Italy 
 
 FSHD, the third most common myopathy, is an autosomal dominant disorder whose genetic 
locus maps to chromosome 4 (4q35). 
 Unlike the majority of genetic diseases, FSHD is not due to a mutation within a protein-coding 
gene. Instead, FSHD is caused by reduction in the copy number of a 3.3 kb repeated sequence called 
D4Z4. Loss of D4Z4 causes an epigenetic alteration leading to de-repression of three 4q35 genes: 
FRG1, FRG2 and ANT1. 
 D4Z4 is highly polymorphic and in healthy subjects the number of repeats can range from 11 to 
100 units, while FSHD patients carry less than 11 units. The number of D4Z4 repeats is a critical 
determinant of the age of onset and clinical severity of FSHD. In general, fewer repeats are associated 
with a more severe phenotype that presents in childhood. Paradoxically, individuals completely devoid 
of D4Z4 are normal suggesting that at least one copy of D4Z4 is required to cause FSHD, possibly 
through a gain-of-function mechanism. 
 We found that a chromatin-bound non-protein coding RNA (ncRNA) is transcribed proximally 
to D4Z4 selectively in the skeletal muscle of FSHD patients and in FSHD myotubes. Intriguingly, in 
several experimental systems production of the ncRNA correlates with de-repression of 4q35 genes. 
Notably, knockdown of the ncRNA prevents 4q35 gene de-repression. 
 We used chromosome conformation capture to study the spatial organization of the 4q35 
chromatin. We found that 4q35 gene de-repression is associated to a reorganization of the 4q35 
chromatin. Interestingly, the ncRNA is required for this chromatin reorganization to take place. 
Based on our preliminary results, we propose that the ncRNA activates the epigenetic cascade 
culminating with 4q35 gene de-repression in FSHD. 
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5. 
 
Chromatin modification at DNaseI hypersensitive sites in 4q35 in myoblasts 
 
Jing-Jing Ma1, Shao-Chi Chang1, Xueqing Xu1, Dmitri Loukinov2, Victor Lobanenkov2, and Melanie 
Ehrlich1 
 
1Human Genetics Program and the Department of Biochemistry, Tulane Medical School, New 
Orleans, Louisiana 70112 USA  
2Molecular Pathology Section, National Institute of Allergy and Infectious Diseases, Rockville, 
Maryland  20852 USA 
 
Evidence suggests that changes in chromatin structure at 4q35 play a major role in 
facioscapulohumeral muscular dystrophy (FSHD). Although there are many parameters defining 
chromatin structure, some are of special importance. Among these are dimethylation of histone H3 at 
lysine 4 (H3K4me2), which is enriched in enhancers and promoters, and binding of the transcription 
factor and insulator protein CTCF. In collaboration with Greg Crawford, our lab has begun studying 
the structure of chromatin throughout 4q35.2 using high-resolution methods. First, we mapped 
DNaseI-hypersensitive sites (DHS), markers of promoters, enhancers, and silencers that are active or 
poised for activity. From our analysis with tiling arrays on three FSHD and three control myoblast cell 
strains (Xu et al., Nucleic Acids Res., Oct 9, Epub ahead of print, 2009) and next-generation 
sequencing on another three control strains (unpublished results), we found several tissue-specific 
DHS in two large gene deserts in 4q35.2. One of these DHS was found preferentially in FSHD 
myoblasts and is located 272 kb proximal to the FSHD-linked D4Z4 tandem repeat. It was the closest 
unique-sequence DHS to D4Z4 other than the DHS at the promoter of FRG1.  
In the present study, we used chromatin immunoprecipitation (ChIP) with specific antibodies, 
to test whether these DHS regions, all of which are far from genes, are enriched for H3K4me2 relative 
to randomly chosen non-gene and non-DHS sequences. Three myoblast cell strains were tested, 
namely, control fetal myoblasts, biopsy-derived control myoblasts, and myoblasts from a patient with 
clinical symptoms of FSHD but without a demonstrated short D4Z4 array. Two amplicons from each 
DHS were analyzed by real-time qPCR of the immunoprecipitate vs. the input chromatin. The FSHD-
preferential DHS and three other gene-desert DHS were all enriched for H3K4me2, usually about 4-to-
30 fold compared to the average signal from three negative-control amplicons. The enrichment for a 
transcription-associated chromatin mark at these DHS located more than 0.1 or 0.5 Mb from the 
nearest known gene indicates that even the gene deserts at 4q35.2 need to be considered for possible 
FSHD-related roles in cis to a short FSHD-causing D4Z4 array. It has been postulated that long 
distance looping at 4q35.2 may be involved in FSHD. Therefore, these DHS with marks of active 
chromatin are of interest to examine for looping with D4Z4. Preliminary results from ChIP with 
antibodies to CTCF, a protein implicated in long-distance looping, indicate that the FSHD-preferential 
DHS was enriched in CTCF in fetal myoblasts. This CTCF enrichment is of special interest because of 
the finding of Ottaviani et al. (PLoS Genet. 5:e1000394, 2009) that CTCF binds to D4Z4. To look for 
postulated pathogenic long-range interactions involving these and other sites in 4q35.2, we are testing 
for chromatin looping by two methods. (Supported by NIH Grant NS048859-S2) 
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6.  
 
Specific loss of histone H3 lysine 9 trimethylation and HP1/cohesin binding at D4Z4 repeats is 
associated with facioscapulohumeral dystrophy (FSHD) 
 
Weihua Zeng, 1 Jessica C. de Greef, 2 Yen-Yun Chen, 1 Richard Chien, 1 Xiangduo Kong, 1 Heather C. 
Gregson, 1 Sara T. Winokur, 1 April Pyle, 3 Keith D. Robertson, 4 John A. Schmiesing, 1 Virginia E. 
Kimonis, 5 Judit Balog, 2 Rune R. Frants, 2 Alexander R. Ball, Jr., 1 Leslie F. Lock, 1 Peter J. Donovan, 1 
Silvère M. van der Maarel, 2 and Kyoko Yokomori1 
 
1 Department of Biological Chemistry, School of Medicine, University of California, Irvine, California 
92697-1700  USA  
2 Leiden University Medical Center, Center for Human and Clinical Genetics, P.O. Box 9600, 2300 RC 
Leiden, the Netherlands 
3 Institute for Stem Cell Biology and Medicine, Department of Microbiology, Immunology and 
Molecular Genetics, David Geffen School of Medicine at UCLA, 277A BSRB Box 951489, Los 
Angeles, California 90095-1489  USA 
4 Department of Biochemistry and Molecular Biology, University of Florida, Box 100245, Gainesville, 
Florida 32610  USA  
5 Division of Medical Genetics and Metabolism, Department of Pediatrics, University of California 
Irvine Medical Center, 101 The City Drive South, ZC4482, Orange California 92868  USA 
 
 Facioscapulohumeral dystrophy (FSHD) is an autosomal dominant muscular dystrophy in 
which no mutation of pathogenic gene(s) has been identified. Instead, the disease is, in most cases, 
genetically linked to a contraction in the number of 3.3 kb D4Z4 repeats on chromosome 4q. How 
contraction of the 4qter D4Z4 repeats causes muscular dystrophy is not understood. In addition, a 
smaller group of FSHD cases are not associated with D4Z4 repeat contraction (termed "phenotypic" 
FSHD), and their etiology remains undefined. We carried out chromatin immunoprecipitation analysis 
using D4Z4-specific PCR primers to examine the D4Z4 chromatin structure in normal and patient cells 
as well as in small interfering RNA (siRNA)-treated cells. We found that SUV39H1-mediated H3K9 
trimethylation at D4Z4 seen in normal cells is lost in FSHD. Furthermore, the loss of this histone 
modification occurs not only at the contracted 4q D4Z4 allele, but also at the genetically intact D4Z4 
alleles on both chromosomes 4q and 10q, providing the first evidence that the genetic change 
(contraction) of one 4qD4Z4 allele spreads its effect to other genomic regions. Importantly, this 
epigenetic change was also observed in the phenotypic FSHD cases with no D4Z4 contraction, but not 
in other types of muscular dystrophies tested. We found that HP1[gamma] and cohesin are co-recruited 
to D4Z4 in an H3K9me3-dependent and cell type-specific manner, which is disrupted in FSHD.  The 
results indicate that cohesin plays an active role in HP1 recruitment and is involved in cell type-
specific D4Z4 chromatin regulation. Taken together, we identified the loss of both histone H3K9 
trimethylation and HP1[gamma]/cohesin binding at D4Z4 to be a faithful marker for the FSHD 
phenotype. Based on these results, we propose a new model in which the epigenetic change initiated at 
4q D4Z4 spreads its effect to other genomic regions, which compromises muscle-specific gene 
regulation leading to FSHD pathogenesis.  
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 Sir Andrew Huxley has said that if scientists in the mid-twentieth century had been less 
obsessed with the then new science of biochemistry and had also looked  to the early twentieth century 
studies of muscle morphology, they would have discovered that ‘sliding filaments’ cause muscle 
contraction long before his own paper (and that of another group) on that subject appeared in ‘Nature’ 
in 1954.  
 The purpose of the present discussion is to correlate ‘traditional’ (1950s and earlier) studies of  
human embryology with both the clinical manifestations of FSHD (as it affects muscle and retina) and 
the most recent concepts of muscle development which focus on signaling pathways (wnt especially) 
and ‘patterns of transcription factors’. 
 The geneal association of FSHD with asymptomatic  peripheral retinal vasculopathy which 
occasionally results in symptomatic ‘Coats syndrome’ is well established. ‘Coats Disease’ is part of a 
spectrum of sporadic or genetic vascular disorders which includes  ‘Norrie Disease’ and  Familial 
Exudative Vitreoretinopathy (FEVR)’. All are caused by similar developmental asymmetric 
abnormalities of peripheral retinal blood vessels. They can be caused by mutations affecting ligand 
(such as norrin)  or receptors/co-receptors (such as frizzled-4 and LRP5) of  wnt signaling pathways .   
 Given the complexity of wnt signaling pathways, and the pivotal role of both the canonical and 
planar polarity wnt pathways in myogenesis and regeneration, I previously postulated that aberration in 
other components of wnt signaling might cause muscle weakness by impairing regeneration in FSHD. 
There is a developing literature on the  interactions between wnt pathways and transcription factors in 
proliferating myoblasts .  
 Not all facial muscles   are normally affected in FSHD. Patterns of embryonic facial human 
development illustrated by R M Patten (1953)  and others show that in humans the affected facial 
expression muscles derive virtually exclusively from the second branchial arch.  Recent work of R G 
Kelly and others show that patterns of signaling, and of redundancies of myogenic transcription 
factors, in facial muscles differ radically from those in other muscles – AND that these patterns also 
differ in  each of the four branchial arches which become face muscles.  PAX3 is absent from 
embryonic face muscle. 
 There are further complexities. FEVR has been described in DiGeorge Syndrome (due to 
mutated TBx1 – a transcription factor which interacts with VEGF1 and is present in the first human 
two branchial arches) .  Coats Disease may occur in the Cornelia de Lange Syndrome (caused by  
mutation affecting cohesion - now implicated in FSHD). 
 Further knowledge about the selective spatial and temporal patterns of signaling and 
transcription factors in human muscles - especially those derived from the second branchial arch - 
selectively affected in FSHD may give clues to its pathogenesis and treatment. Might a regional 
absence of redundancy predispose to clinical expression?  
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 As one of our approaches to identify and validate FSHD mRNA biomarkers, we are using a 
micro-qPCR array system (Fluidigm Biomark 48.48) to quantify and compare gene expression in 
FSHD and control muscle biopsies and cultured myogenic cells. In initial studies, we analyzed both 
biopsies and cell cultures for a panel of genes that consisted largely of FSHD candidates and 
housekeeping genes (for normalization).  Cultures were additionally analyzed for a second set of genes 
that consisted largely of markers of terminal differentiation.  The qPCR assays were highly 
reproducible for both biopsies and cultures, with standard errors of only ~0.1- 0.2 cycle over a wide 
range of expression levels.  In addition, genes with generally stable expression in both biopsies and 
cultures were identified for use in normalization (e.g., HPRT1, PPIA).    
For the biopsies, we carried out quadruplicate qPCR analyses of a total of 25 biopsies, 
including biceps and deltoid samples from eight FSHD patients and four healthy siblings and an 
additional FSHD deltoid sample.  Biopsies came from a total of six families.  Initial results suggest that 
expression of particular genes may depend on family origin and extent of disease progression, as well 
as on D4Z4 status.   
For cultured cells, we grew CD56-positive myogenic cells obtained from an FSHD patient, a 
healthy sibling, and an alpha-sarcoglycan (SGCA)-deficient LGMD2D patient.  Cells were cultured in 
two different laboratories, two growth media, and two differentiation media.  Cultures were harvested 
in the proliferation phase or after four days of differentiation. The qPCR assays showed that expression 
in proliferating myoblasts was sensitive to culture conditions.  In this first experiment, expression of 
differentiation markers (e.g., myosin heavy chains, MyoD, myogenin) was consistently lower in FSHD 
than in healthy or SGCA-deficient cultures.   
In one case, we had data from biopsies and cultures derived from a paired FSHD patient and 
healthy sibling.  We found that genes that were highly expressed in culture tended to be highly 
expressed in the corresponding biopsy.  Also, a group of inflammation-related genes were more highly 
expressed in biopsies than in cultures, consistent with a non-myogenic cell origin in the biopsies.  
Though many genes showed very similar levels of expression in the cultures and the biopsies, other 
genes showed higher expression in the culture or in the biopsy.  Though definitive conclusions await 
comparisons of larger numbers of FSHD and control biopsies and cultures, these initial experiments 
demonstrate that micro-qPCR arrays are a robust method for quantitative comparisons of gene 
expression in FSHD and control biopsies and cells. 
 
Supported by grants from the NIH, Boston Biomedical Research Institute and the FSH Society. 
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 Introduction: In <5% of patients with facioscapulohumeral muscular dystrophy (FSHD) no 
D4Z4 repeat contraction on chromosome 4q35 can be identified. Yet, in common with FSHD1 patients 
with D4Z4 contraction, these so-called FSHD2 patients show loss of DNA methylation and 
heterochromatin markers at the D4Z4 repeat. This suggests that a defect in chromatin structure of the 
D4Z4 repeat underlies FSHD2. 
 Objective: To date there has been no comprehensive clinical study of FSHD2. The purpose of 
our study was to critically evaluate the clinical features in FSHD2 patients in order to establish whether 
these patients represent true phenocopies of FSHD1 and to establish (epi) genotype-phenotype 
correlations. 
 Methods: Using pulsed field gel electrophoresis we determined D4Z4 repeat size. We used 
methylation-sensitive Southern blot analysis to determine D4Z4 methylation on chromosomes 4 and 
10. Using a standardized clinical evaluation form recently developed by the Fields Center, we 
clinically evaluated all patients. 
 Results: We identified 26 FSHD2 patients in 22 families carrying a normal-sized D4Z4 repeat 
(≥40 kb) with prominent D4Z4 hypomethylation. All patients carry at least one D4Z4 repeat on the 
pathogenic haplotype 4qA161 and in most patients (23/26) the smallest D4Z4 repeat on the 4qA161 
allele is <80 kb in size. In contrast, only 25% of 4qA161 alleles in the Dutch population is <80 kb. In 
contrast to FSHD1, most FSHD2 patients are sporadic (70%).  The pattern of clinical involvement in 
FSHD2 is identical to FSHD1. In the present cohort there was a slight predominance of males (65%) 
but there were no gender differences in average age at onset or clinical severity scores.  
 Conclusions: We conclude that in order to develop FSHD2 a hypomethylated and medium-
sized D4Z4 repeat on the pathogenic haplotype 4qA161 is necessary. Clinically, these patients are 
indistinguishable from patients with FSHD1. This new cohort of FSHD2 patients provides further 
evidence that FSHD2 represents a true phenocopy of FSHD1. 
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 Inhibition or loss of the TGF-Beta family member, myostatin, leads to increased muscle mass 
and strength in animals and humans.  In animal models of muscular dystrophy, myostatin inhibition 
stimulates regeneration and inhibits fibrosis.  The first clinical trial of an inhibitor of myostatin in 
human disease was with a neutralizing antibody, MYO-029.  Although this trial showed positive trends 
in FSHD, there were several limitations to the trial.  The greatest limitation was that it remained 
unclear at the conclusion of the trial if the drug did not adequately inhibit myostatin or if it inhibited 
myostatin but did not have a significant effect on muscle strength.  So that the FSHD community does 
not repeat this experience with novel therapeutics in development, it is critical to develop accurate 
biomarkers of myostatin inhibition.  In our efforts to develop a specific biomarker of postnatal 
myostatin inhibition in skeletal muscle, we have compared the gene expression patterns of muscle 
from mice postnatally treated with ActRIIB.Fc  (a broader inhibitor of TGF-Beta family members) 
with muscle from  myostatin null mice.  We assessed global gene expression profiling in quadriceps 
and soleus muscles obtained from mice treated with ActRIIB.Fc over one and two weeks, from Mstn-/- 
and control mice using the Affymetrix GeneChip® 1.0 ST arrays.  There was a significant overlap in 
up and downregulated genes in both muscle types between mice treated for two weeks with 
ActRIIB.Fc and Mstn-/- mice (P<0.0001).  Furthermore, we validated expression of 30 genes that 
showed the most significant up and downregulation on arrays with quantitative real-time PCR using 
TaqMan gene expression assays on Fluidigm’s BioMark™ microfluidic dynamic arrays.  There was a 
strong correlation between microarray results and quantitative real-time PCR with a correlation 
coefficient of over 0.9.  Our results demonstrate the feasibility of developing a biomarker of myostatin 
inhibition in skeletal muscle.  
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 Over the years, cell and animal models for FSHD have been generated by specific over-
expression of individual candidate genes. However, given the controversy of transcriptional 
deregulation of these genes in FSHD muscle, the relevance of these models remains uncertain. 
 Moreover, there are currently no good human cellular models for FSHD. Primary myoblast cell 
cultures are available but they have limited replicative capacity and suffer from large inter-individual 
variation. Here we present preliminary results showing that the shortcomings of primary human 
myoblast cell cultures can be overcome by immortalization of myoblast cell culture derived from 
FSHD patients.  
Taking advantage of the high frequency of somatic mosaicism in FSHD, we immortalized myoblast 
cell cultures derived from affected muscle of five mosaic FSHD patients. By clonal expansion, we 
were able to generate pairs of clonal myogenic cell lines with or without contraction. Thus, these cell 
lines are isogenic with exception of the D4Z4 contraction.  
 Preliminary studies demonstrate that these cell lines retain their myogenic properties, 
differentiate into multinucleated myotubes, and show no overt deregulation of the subtelomerically 
located FRG1 as a consequence of hTERT transgene expression. 
 We propose that their immortality and isogenicity will overcome issues of inter-individual 
variation and thereby make them ideal cell lines to further study the pathogenic mechanism of FSHD 
and to be used in high throughput small molecule screens.  
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 There is currently no animal model bearing the actual FSHD mutation (D4Z4 contraction), and 
the lack of a suitable model system to study the effects of this mutation has severely hampered 
progress in understanding FSHD. In an effort to shed light on the disease mechanism and to speed a 
potential cell therapy, we have derived iPS cells from myoblast cultures taken from FSHD patients and 
controls.  We present preliminary data on the differentiation of these cells through mesoderm and into 
muscle, and the expression of FSHD candidate genes along this developmental pathway.  We compare 
these cells to mouse embryonic stem cells that we have engineered to carry FSHD mutation-bearing 
DNA constructs at a euchromatic site on the X chromosome and discuss the roadblocks to the 
application of iPS cells to cell therapy for FSHD. 
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 The majority of individuals with Facioscapulohumeral Muscular Dystrophy (FSHD) have a 
shortened array of D4Z4 repeats linked to a specific inherited haplotype located on the long arm of 
chromosome 4. Shortened disease-causing D4Z4 arrays and D4Z4 arrays from individuals with 
FSHD2 have also been shown to be hypomethylated suggesting that aberrant transcriptional regulation 
of D4Z4 sequences may be an important component of FSHD pathology. Homeotic transcription 
factors are important regulators of stem cell fate and thus DUX4 may normally have a spatiotemporally 
regulated expression pattern that is disrupted in individuals with FSHD. To determine the pattern of 
DUX4 expression during development, we localized cells containing β-galactosidase activity during 
mouse embryogenesis using a transgenic mouse containing the human DUX4 promoter and a LacZ 
reporter gene. In addition, we’ve generated and characterized induced pluripotent stem (IPS) cells from 
fibroblasts of FSHD-affected individuals. We demonstrate that these cells are pluripotent using a 
mouse teratoma assay, and show that they can be differentiated to NCAM(+) cell populations in culture 
providing a human cell culture model to study changes in developmentally-regulated transcription 
associated with D4Z4 array contraction and/or methylation.  
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 We identified a double homeobox gene (DUX4) within each D4Z4 unit at the FSHD locus that 
is activated in muscle cells following the FSHD deletion (Gabriels et al., 1999; Kowaljow et al., 2007; 
Dixit et al., 2007). Collaboration with M. Kyba and Y.W. Chen’s groups showed that DUX4 was a 
transcription factor targeting a number of genes, some of which encode other transcription factors. 
Among others, DUX4 inhibited MYOD gene expression, leading to myoblast differentiation defects, 
inhibited genes involved in response to oxidative stress, and activated expression of PITX1 that is 
involved in muscle atrophy (Bosnakovski et al., 2008; Dixit et al., 2007). 
 Since we detected DUX4 expression in differentiating myoblasts, we chose to compare the 
proteome of FSHD and control myotubes by gel free differential mass spectrometry analysis using an 
isotope coded protein labelling (ICPL) on free amines (NH2 termini and lysines). 
 In keeping with a differentiation defect in FSHD we observed increased amounts of vimentin, 
an intermediate filament protein only expressed in early myogenesis. A putative DUX4 binding site 
was found in the vimentin promoter. A 4-fold induction of luciferase activity was observed when we 
co-transfected C2C12 cells with a DUX4 expression vector and a luciferase reporter gene fused to the 
vimentin promoter. In addition, galectin-1 that is normally decreased during differentiation remained at 
higher levels in FSHD myotubes.  Both the vimentin and galectin1 increases in FSHD myotubes were 
confirmed by specific immunodetection on Western blots.  
 In addition, the ICPL study indicated a general decrease of cytoskeletal and contractile proteins 
that might reflect an atrophy-associated proteolysis as well as differentiation defects.  
Our data also confirmed a mitochondrial dysfunction in FSHD: enzymes involved in fatty acid β-
oxidation, Kreb’s cycle and the electron transport chain were decreased. There was no change in 
glycolytic enzymes but an increase of lactate dehydrogenase in FSHD myotubes. This observation was 
validated by increased lactate accumulation in the culture medium that was detected by a 
metabonomics analysis (1H Nuclear Magnetic Resonance).  
 
- Bosnakovski D, Xu Z, Gang EJ, Galindo CL, Liu M, Simsek T, Garner HR, gha-Mohammadi S, Tassin A, Coppee F, 
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associated molecular pathologies. EMBO J 27:2766-2779. 
- Dixit M, Ansseau E, Tassin A, Winokur S, Shi R, Qian H, Sauvage S, Matteotti C, van Acker AM, Leo O, Figlewicz D, 
Barro M, Laoudj-Chenivesse D, Belayew A, Coppee F, Chen YW. 2007 Nova. DUX4, a candidate gene of 
facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci U S A 
104:18157-18162. 
- Gabriëls J, Beckers MC, Ding H, De Vriese A, Plaisance S, van der Maarel SM, Padberg GW, Frants RR, Hewitt JE, 
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 Insufficient understanding of the pathogenic mechanisms underlying FSHD has hindered 
development of effective therapies. RNAi therapy is emerging as an important strategy to treat 
dominant genetic disorders, like FSHD, but this approach requires specific gene targets.  Toward this 
end, we are investigating the role of several candidate genes in FSHD development.  DUX4 is an 
excellent FSHD candidate gene because of its location in the D4Z4 repeat, elevated expression in 
FSHD myoblast cultures, and pro-apoptotic function in vitro.  Here, we describe in vivo evidence that 
DUX4 over-expression causes histological and functional deficits consistent with muscular dystrophy 
in two animal models, zebrafish and mice.  For the former, we used the Tol2 transposon system and 
striated muscle-specific MHCK7 promoter to express DUX4 or control GFP genes in embryonic 
zebrafish muscle.  Using GFP epifluorescence as an indicator, we found that gene expression was 
restricted to somites with weaker staining in heart.  In DUX4-injected fish, muscle-specific DUX4 
expression produced body malformations, impaired mobility, somite defects, and myofiber 
degeneration.  These results are consistent with abnormalities reported in other zebrafish models of 
muscular dystrophy and indicate that DUX4 is toxic to developing eukaryotic muscle.  To confirm 
DUX4 toxicity in a mammalian model more closely related to humans, we delivered adeno-associated 
viral vectors (AAV6) carrying DUX4 or control GFP vectors to neonate or adult mouse muscle.  In 
neonatal mice, DUX4 caused significant muscle atrophy, increased central nucleation, myofiber size 
variability, fibrosis, fat replacement of muscle, and inflammatory cell infiltration, while control GFP or 
untransduced muscles were unaffected.  These results confirm our findings in zebrafish, and indicate 
that DUX4 toxicity to developing muscle is conserved between eukaryotic species.  In adult muscle, 
AAV6.DUX4 produced massive, dose-dependent myofiber degeneration, apoptosis, histological 
evidence of muscle turnover, mononuclear cell infiltration, and gross muscle weakness.  Untransduced 
or GFP transduced myofibers were normal. To confirm the apoptotic nature of DUX4.V5 over-
expression is a function of the protein and not a side effect of nonspecific over-expression, we made 
rational mutations in the DUX4 homeobox 1 DNA binding domain (HOX1 DBD).  Specifically, we 
changed 5 highly conserved HOX1 DBD amino acids to alanines, determined protein expression by 
western blot and immuofluorescence staining, and confirmed that it was incapable of binding DNA 
using gel shift assays with a PITX1 promoter probe.  Importantly, the DUX4.HOX1 mutant did not 
cause apoptosis in cultured cells, and when delivered to adult mouse muscle using AAV6 vectors, the 
HOX1 mutations prevented DUX4-mediated myotoxicity, as muscles were indistinguishable from wild 
type or control treated mice using several histological and functional tests.  These data support that 
DUX4 toxicity is related to its ability to bind DNA and stimulate transcription, thereby suggesting that 
DUX4-stimulated downstream gene targets may contribute to FSHD.  Moreover, together with 
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numerous recent studies, our data justifies further investigation into the potential role of DUX4 as an 
FSHD candidate gene. 
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 Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant condition, which 
in the majority of cases, is linked to contraction of the D4Z4 repeat array in the sub-telomeric region of 
chromosome 4q. It is unclear how this contraction results in FSHD though, but one theory is that it 
modifies the expression profiles of neighbouring genes, including FRG1 and DUX4c. The D4Z4 region 
also contains an open reading frame that encodes for a double homeobox containing protein - DUX4. 
 While muscle fibres are clearly affected in FSHD, it is currently unclear whether satellite cell 
dysfunction also contributes to disease progression in this condition. In this study, we have examined 
the effects of several FSHD candidate genes (FRG1, DUX4 and DUX4c) on satellite cell function, 
using our isolated murine myofibre model (Zammit et al., 2004). Retroviral-mediated constitutive 
expression of human FRG1 had no obvious effects on satellite cell proliferation, differentiation or self-
renewal. In contrast, both human DUX4 and DUX4c had marked effects on satellite cells. Constitutive 
expression of DUX4 was toxic to satellite cells, consistent with previous observations in C2C12 
myoblasts (Bosnakovski et al., 2008). Human DUX4c inhibited myogenic progression and maintained 
satellite cells in a “quiescent-like” state. Preliminary results show that DUX4c-expressing satellite cells 
accumulated β-catenin protein in their nuclei. This may disrupt canonical Wnt signalling in satellite 
cells (Perez-Ruiz et al., 2008), thereby perturbing their myogenic differentiation and ability to 
effectively repair/regeneration muscle. Speculatively, altered expression of DUX4 and DUX4c in the 
satellite cells of FSHD patients would diminish the efficiency of muscle repair, contributing to muscle 
wasting and disease progression.  
 
 
Bosnakovski, D., Xu, Z., Gang, E. J., Galindo, C. L., Liu, M., Simsek, T., Garner, H. R., Agha-
Mohammadi, S., Tassin, A., Coppee, F., Belayew, A., Perlingeiro, R. R., and Kyba, M. (2008). 
An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated 
molecular pathologies. Embo J 27, 2766-79. 
Perez-Ruiz, A., Ono, Y., Gnocchi, V. F., and Zammit, P. S. (2008). b-catenin promotes self-renewal of 
skeletal-muscle satellite cells. J Cell Sci 121, 1373-82. 
Zammit, P. S., Golding, J. P., Nagata, Y., Hudon, V., Partridge, T. A., and Beauchamp, J. R. (2004). 
Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? J Cell Biol 166, 
347-57. 
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Facioscapulohumeral muscular dystrophy region gene-1 (FRG-1) is an actin bundling protein 
associated with muscle attachment sites 
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In vertebrates, over-expression of facioscapulohumeral muscular dystrophy (FSHD) region 
gene 1 (FRG1) recapitulates the pathophysiology exhibited by FSHD patients, though FRG1’s role in 
FSHD is still controversial and no precise function for FRG1 has been described in any organism.  To 
gain insight on FRG1’s function and potential role in FSHD, we analyzed the highly conserved 
Caenorhabditis elegans ortholog, frg-1.  C. elegans body-wall muscles contain two distinct subcelluar 
pools of FRG-1; nuclear FRG-1, concentrated in the nucleoli, and cytoplasmic FRG-1 associated with 
the Z-disk/costamere-like structures called dense bodies.  Functionally, we demonstrate that FRG-1 is 
an F-actin bundling protein, consistent with its localization to dense bodies.  This is particularly 
intriguing because it places FRG-1 along side the list of dense body components whose vertebrate 
orthologs are involved in myriad myopathies associated with disrupted costameres and Z-disks.  
Interestingly, over-expressed FRG-1 preferentially accumulated in the nucleus and, when over-
expressed specifically from the frg-1 promoter, disrupted the adult ventral muscle structure and 
organization.  Together, these data further support a role for FRG1 over-expression in FSHD 
pathophysiology and identify a previously unsuspected role of FRG-1 being directly associated with 
the muscle structure and integrity. 
 
Funded by NIH/NIAMS grant 1RO1AR055877 
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 Although the genetic lesion leading to Facioscapulohumeral Dystrophy (FSHD) has been 
known for around fifteen years, the downstream epigenetic consequences and how they lead to patient 
pathology remain unclear. Upregulation of a local 4q35 gene has emerged as the most likely model. 
Using the power of Xenopus laevis as a system for vertebrate development, our lab has previously 
studied the effects of loss and gain of one of the best candidates for FSHD, Frg1. We showed that 
FRG1 is critical to both muscle and vascular development. Further, we found that increased levels of 
FRG1 led to abnormal muscle and increased angiogenesis, the two most prominent symptoms of 
FSHD.  Here, we have used the same model system to study the effects of other promising candidates 
including DUX4, PITX1, and DUX4C.  We found that expression of DUX4 or PITX1 from embryonic 
mRNA injections led to massive cellular loss leading to abnormal development restricted to the 
expressing side of the embryos and these abnormalities were not muscle specific.  Similarly, we 
examined the effects of DUX4C expression within our model and found no effects on muscle 
development.  We conclude that only elevated Frg1 levels during Xenopus development, and not 
DUX4, DUX4C, or PITX1, leads to a phenotype resembling the pathology observed in FSHD patients. 
 
Funded by NIH/NIAMS grant 1RO1AR055877 
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Mu-Crystallin and the Pathogenesis of FSHD 
 
Patrick W. Reed and Robert J. Bloch 
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 We have reported a large, specific increase in the levels of mu-crystallin (CRYM) in the 
soluble fractions prepared from deltoid muscles of patients with FSHD, but not from healthy controls 
or patients with inflammatory myopathies or other muscular dystrophies.  Here we use electroporation 
to introduce mammalian expression plasmids encoding green fluorescent protein (GFP) or CRYM in 
the tibialis anterior skeletal muscles of mice to test the hypothesis that high levels of CRYM are toxic 
to skeletal muscle in vivo. We used the CMV promoter to drive high levels of gene expression. 
 In vivo gene transfection (IVGT) by electroporation led to high levels of CRYM or GFP, as 
assessed by immunofluorescence and immunoblotting. As electroporation alone causes muscle 
damage, we waited for 4 weeks or longer before examining transfected muscles.  At 4 weeks after 
transfection, TA muscles expressing GFP showed little or no evidence of ongoing muscle pathology. 
Muscles expressing high levels of CRYM showed muscle pathology, as evidenced by inflammation, 
muscle fiber turnover (small caliber fibers expressing a development MHC), and increases in centrally 
nucleated fibers (CNFs).  Many fibers expressing CRYM were adjacent to fibers that did not express 
the protein but that had central nuclei.  Similar studies at longer times after transfection continued to 
show no evidence of ongoing pathology associated with GFP expression, but fibers expressing CRYM 
decreased in number gradually, until at 4 months no such fibers remained.  CNFs persisted in the latter, 
however. These results suggest that muscle fibers that overexpress CRYM die and are replaced with 
healthy fibers over a period of 4 months.   We obtained similar results, but with a milder myopathy, 
when CRYM was expressed following IVGT under the control of the human skeletal actin promoter, 
which more closely matches expression levels with those we’ve observed in skeletal muscles of 
patients with FSHD.  Our results suggest that sustained over-expression of CRYM at levels similar to 
those seen in muscles from patients with FSHD are sufficient to cause skeletal myopathy.  
 
Supported by the FSH Society, the Muscular Dystrophy Association, and the NIH (1 U54-NS063381, 
to C. Emerson) 
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Human FRG1 is a cytoplasmic actin bundling protein and a nuclear RNA associated protein 
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FRG1 is one of the leading candidate genes for FSHD pathogenesis.  The precise function of 
FRG1 is not known, however, several lines of evidence suggest FRG1 is a nuclear protein involved 
with aspects of RNA biogenesis.  FRG1 is very highly conserved in vertebrates and invertebrates and 
putative domain analysis predicts two highly conserved nuclear localization signals (NLS), and a 
conserved fascin-like domain, yet sequence analysis of FRG1 fails to predict any RNA-binding motifs.  
To better understand the function of FRG1, we performed structure-function analysis of human FRG1.  
We found FRG1 associates with newly transcribed RNA using Xenopus laevis lampbrush chromosome 
spreads.  Furthermore, in human cells we demonstrated FRG1 interacts with numerous RNA 
transcripts by RNA-IP.  These data are consistent with a role for nuclear FRG1 in RNA biogenesis.  
The presence of a conserved fascin-like domain suggests FRG1 interacts with or bundles F-actin, a 
function normally reserved for cytoplasmic proteins.  Interestingly, we have recently described a 
cytoplasmic pool of endogenous FRG1 in human, mouse, frog, and C. elegans.  To determine if FRG1 
with its fascin domain is a bona fide actin bundling protein, we performed in vitro actin bundling 
assays.  Using human recombinant FRG1 we show that FRG1 robustly bundles F-actin in vitro and 
have characterized this activity.  Overall, we conclude that human FRG1 is a RNA binding protein 
when in the nucleus and an actin bundling protein when in the cytoplasm, or when present at the 
muscle attachment sites. 
 
Funded by NIH/NIAMS grant 1RO1AR055877 
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Initial results from single subcutaneous administration of ACE-031, a form of the soluble activin 
type IIB receptor, in healthy postmenopausal volunteers 
 
Borgstein N.G.*, Yang Y.*, Condon C.H.*, Wilson D.M.*, Haltom E.*, Larouche R.#, Lachey J.L.*, 
Seehra J.*, Sherman M.L.*  
 
*Acceleron Pharma, Cambridge, Massachusetts, USA; #Anapharm, Montreal, Canada 
 
 ACE-031 is a novel, fully human, fusion protein derived from the extracellular domain of the 
human activin receptor type IIB (ActRIIB) linked to the Fc portion of human IgG1. ACE-031 binds to 
and prevents myostatin and other members of the TGF-b superfamily from signaling through ActRIIB.  
In numerous animal studies, administration of an ActRIIB-Fc fusion protein results in increased 
muscle mass and strength and increased bone mineral density, in both normal animals and models of 
disease.  In this first-in-human, randomized, double-blind Phase 1 study, the safety and tolerability of 
single, escalating doses of ACE-031 in healthy postmenopausal women were evaluated.  Secondary 
outcomes included assessments of the pharmacokinetic and pharmacodynamic properties of ACE-031.  
Forty-eight subjects received ACE-031 or placebo subcutaneously at dose levels ranging from 0.02 to 
3 mg/kg.  ACE-031 was safe and well tolerated with a linear PK profile and a t1/2 ranging from 10-15 
days.  
Increases in lean body mass (LBM) as measured by DXA were observed as early as 15 days following 
ACE-031 administration and were maintained at 2 months post treatment (2.6 % mean maximum 
increase from baseline).  Changes in serum biomarkers of pharmacologic activity were observed 
including increases in adiponectin and decreases in leptin consistent with increased fat metabolism.  
Increases in bone formation biomarker (bone specific alkaline phosphatase) and decreases in the bone 
resorption biomarker (s-CTX) were also observed.   
 Treatment with a single-dose of ACE-031 was well-tolerated and resulted in significant, rapid, 
and sustained increases in lean body mass. These data support the development of ACE-031 in 
neuromuscular diseases such as DMD, FSHD and ALS to increase muscle strength and improve 
physical function. 
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muscular dystrophy locus FSHD1A 
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 DUX4 is a pro-apoptotic protein, leading to cell death in cell transfection assays1,2. A DUX4-
related protein is endogenously expressed in human muscle derived cells1,2, being the DUX4 gene 
specifically transcribed in FSHD myoblasts3. These studies, as well as recent results obtained by 
others5, support the hypothesis that DUX4 is a main potential pathogenic protein in FSHD6. We have 
proposed that abnormal temporal or spatial expression of DUX4 during muscle development may be 
toxic for muscle cells, causing FSHD3. DUX4 is a nuclear protein1-4 and its subcellular localization 
may be required for its function and/or pro-apoptotic effect. In this report we analyze the subcellular 
trafficking of DUX4 using specific mutants for the two previously described4 DUX4 nuclear 
localization signals, NLS1 (RRRR23) and NLS2 (RRKR98) as well as a third potential NLS (i.e. 
NLS3; RRARHPG151) recognized by visual inspection of the DUX4 amino acid sequence. Single, as 
well as combined double and a triple deletion NLSs- mutants, mostly localize to the cell nuclei 
indicating that subcellular trafficking of DUX4 is not mediate by these NLSs4. The effect of mutations 
in NLS1, NLS2 and NLS3 on DUX4-mediated apoptosis was studied using a GFP-based co-
transfection assay developed in our laboratory1-3. The toxic effect of DUX4 was partially abolished in 
the analyzed mutants. These studies address the questions about the molecular domains involved in the 
normal trafficking of DUX4 as well as the domains required for DUX4-mediated cell death. 
 
1Kowaljow W (2003) PhD Thesis, Argentina; 2Rosa AL (2003) FSHD IRCM, Los Angeles, 
California; 3Kowaljow et al (2007) NMD 17, 611-623; 4Ostlund et al (2005) Biochemistry 44, 2378-
2384; 5Bosnakovski et al (2008) EMBO J 27, 2766-2779; 6Dmitriev et al (2009) NMD 19, 17-20. 
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Krüppel-like factor KLF15 Interacts with the D4Z4 enhancer and up regulates the FSHD-
related gene DUX4c 
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 Facioscapulohumeral muscular dystrophy (FSHD), a dominant hereditary disease with a 
prevalence of 1 in 20,000 individuals, is caused by a partial deletion in the subtelomeric D4Z4 repeat 
array on chromosome 4q. Here we show that a strong transcriptional enhancer within the D4Z4 repeat 
unit interacts with the Krüppel-like factor KLF15 and that the expression level of KLF15 regulates the 
activity of the D4Z4 enhancer which, in turns, induces expression of DUX4c in a KLF15-dependent 
manner. During muscle differentiation, increased expression of KLF15 activates the D4Z4 enhancer 
leading to activation of the promoter of the DUX4c gene. Furthermore, we show that KLF15 is 
expressed at higher levels in muscle biopsies from FSHD patients compared to controls. Higher 
expression of KLF15 in muscles of FHSD patients could induce untimely over-expression of DUX4c 
with deleterious effects on muscle cell differentiation. We suggest that the KLF15-controlled D4Z4 
enhancer may play a role in normal and pathological development of muscular cells.  
 
Key Words: Facioscapulohumeral dystrophy (FSHD)/Transcriptional regulation / Krüppel factor 15/ 
D4Z4 /DUX4c 
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A Window into secrets of myogenesis genes: whole-genome DNaseI hypersensitivity mapping  
 
Melanie Ehrlich1, Koji Tsumagari1, L. Song2, T. S. Fuery2, D. London2, A. P. Boyle2, G. E. Crawford2 
 
1 Human Genetics Program and the Department of Biochemistry, Tulane Medical School, New 
Orleans, Louisiana 70112  USA 
2 Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina 27708  USA 
 
Subregions of 4q35.2 chromatin involved in facioscapulohumeral muscular dystrophy (FSHD), 
including D4Z4, a tandem disease-linked array, probably have special features in skeletal muscle that 
help to make this a predominantly muscle disease. Despite many expression microarray and RT-PCR 
studies, we lack sufficient understanding of FSHD-related gene dysregulation at 4q35.2 and in the rest 
of the genome. To approach these questions from a different vantage point, we began mapping 
DNaseI-hypersensitive sites (DHS) throughout the genomes of myoblast cell strains from unaffected 
individuals before and after differentiation to myotubes to compare these cell types to each other and to 
various non-muscle cell populations. DHS are predominantly known as marks of transcription control 
elements that are nucleosome free or have a loose nucleosome structure. Our analysis of DHS used 
next-generation DNA sequencing (DNase-seq). All active genes and genes poised for activity should 
have a DHS at their promoter. Other active transcription control elements also can have overlapping 
DHS.  
We analyzed myoblast cell strains from three controls and myotubes populations from the same 
three batches of cells. We are comparing their genome-wide DHS maps to those from lymphoblastoid 
cells, hepatoma cells, myeloid cells, osteoblasts, and fibroblasts. No muscle cell-specific DHS were 
seen at the 4q35.2 FRG1, FRG2, or D4Z4.  Just as we found by tiling array analysis, DNase-seq 
revealed muscle-specific DHS in several gene desert regions of 4q35.2 and at genes in the proximal 
portion of 4q35.2.  We have begun data mining across the rest of the genome.  Among our findings are 
the following: 
 
1.) muscle-specific genes with unexpected far-upstream DHS, which are likely to be enhancers;  
2.) muscle-associated genes with myotube-specific DHS;  
3.) muscle-associated genes with myoblast-specific DHS; 
4.) disease-associated genes with muscle-specific internal DHS that probably overlap  
          enhancers, silencers, or alternative promoters;  
5.) known muscle-specific genes with adjacent uncharacterized genes that have a muscle-   
          specific DHS at their promoter. 
 
 These results demonstrate the power of high-resolution mapping of DHS to discover new 
transcription control sequences and unanticipated muscle-associations of poorly characterized genes. 
They lay the foundation for functional analyses and for an ongoing DNase-seq study of FSHD 
myoblasts and myotubes in comparison to controls. (Supported by NIH Grants NS048859 and 
HG003169, the FSH Global Research Foundation, and the National Human Genome Research 
Institute). 
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Studying sequence variation at the human D4Z4 and mouse DUX loci 
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 Facioscapulohumeral muscular dystrophy (FSHD) is caused by contraction of the D4Z4 array 
located on 4q35. Although FSHD is generally believed to be a chromatin-associated disease, the exact 
molecular mechanism is still unclear. Although some models propose that the deletions alter 
expression of genes outside the array; recent studies point towards a direct role for a potential 
homeobox gene, DUX4, that has a copy in each D4Z4 repeat unit. We were intrigued by recent genetic 
studies that demonstrated the requirement of the D4Z4 deletions to occur on particular 4q35 haplotypes 
(notably the 4qA161 haplotype) in order for the deletions to cause FSHD. This indicates the 
importance of one or more specific variants in cis for development of FSHD. 
 Our group is interested in the evolutionary history of DUX genes; we hope that this will inform 
us about the functions of these unusual genes. We recently identified a conserved DUX homeobox 
array in the mouse that may be functionally equivalent to D4Z4. Ectopic expression of high levels of 
either the human or mouse DUX open reading frame causes cell toxicity. We have previously 
demonstrated transcription from the mouse array.  Like the human D4Z4 array, transcription in the 
mouse appears limited to short fragments and we detect both sense and antisense transcripts. It is 
currently unclear whether all or only some of the ~40 DUX copies of the mouse DUX repeat are 
transcribed and are functional.  
 We will present data from our study of sequence variations within the human and mouse DUX 
loci. We have detected a number of variants, some of which are within the coding region and could 
result in functional different DUX proteins. Mapping the relationships between these variants and 
expressed sequences will be important for understanding the normal functions of human and mouse 
DUX genes. Furthermore, such variation within the human array may be important mechanistically in 
FSHD.  
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Endogenous FRG1 protein expression in human and mouse skeletal muscle 
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FRG1 is a candidate gene proposed to be up-regulated in FSHD. While up-regulation of FRG1 
has not been consistently shown in patient samples, over-expression of FRG1 in mouse, Xenopus, and 
C. elegans have all resulted in muscle phenotypes, demonstrating that mis-regulation of FRG1 is 
deleterious to muscle.  To better understand the function of FRG1 we have developed novel highly 
specific antibodies against FRG1 and performed immunostaining for FRG1 in human and mouse 
tissues and cultured cells.  Interestingly we detect both nuclear and cytoplasmic staining for FRG1. 
FRG1 is expressed in skeletal muscle fibers. Other tissues with prominent FRG1 staining include 
smooth muscle, sweat glands and epidermis. This is consistent with previous reports that FRG1 is 
expressed in a wide range of tissue types and points to a common basic cellular function. In support of 
this our group has shown that FRG1 functions in F-actin bundling.  In longitudinal sections of human 
and mouse skeletal muscle FRG1 resides in the sarcomeres giving a striated pattern. This localization 
is conserved down to C. elegans where our laboratory has found FRG-1 localized to the body wall 
muscle dense bodies, structures analogous to the vertebrate Z-disk/costameres.  While a potential role 
for FRG1 in the nucleolus in RNA biogenesis has been proposed, our results suggest an additional role 
for FRG1 in muscle cytoplasm and at the sarcomeres.  This work places FRG1 at the heart of the 
conserved machinery responsible for making muscle attachments and maintaining muscle integrity; 
structures so often disrupted or malfunctioning in many human myopathies. 
 
Funded by NIH/NIAMS grant 1RO1AR055877 
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Both DUX4c and a truncated DUX4 variant perturb beta-catenin localisation in myogenic cells 
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 Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant condition, which 
in the majority of cases, is linked to contraction of the D4Z4 repeat array in the sub-telomeric region of 
chromosome 4q. It is unclear how this contraction results in FSHD. Each D4Z4 repeat array contains 
an open reading frame that encodes a double homeobox containing protein - DUX4, which may be 
aberrantly expressed in FSHD. In addition, the contraction may modify the expression dynamics of 
neighbouring genes including DUX4c. Both DUX4 and DUX4c have been shown to inhibit myogenic 
progression in cell culture (Bosnakovski et al., 2008a; Bosnakovski et al., 2008b). 
 In this study, we have examined the effects of DUX4, DUX4c and several truncated DUX4 
transcripts (a generous gift from S. Tapscott - Snider et al., 2009) on satellite cell function. Retroviral-
mediated constitutive expression of human DUX4c in mouse satellite cells resulted in a nuclear 
accumulation of Beta-catenin protein and inhibited myogenic progression. A proposed truncated 
DUX4 variant lacking the carboxy terminus was also able to induce a similar redistribution of Beta-
catenin in satellite cells, while full-length DUX4 was not. Therefore, the presence of DUX4c and/or 
truncated species of DUX4 may disrupt canonical Wnt signalling in satellite cells (Perez-Ruiz et al., 
2008), so perturbing their myogenic differentiation and ability to effectively repair dystrophic muscle.  
  
 
Bosnakovski, D., Xu, Z., Gang, E. J., Galindo, C. L., Liu, M., Simsek, T., Garner, H. R., Agha- 
Mohammadi, S., Tassin, A., Coppee, F., Belayew, A., Perlingeiro, R. R., and Kyba, M. 
(2008a). An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-
associated molecular pathologies. Embo J 27, 2766-79. 
Bosnakovski, D., Xu, Z., Li, W., Thet, S., Cleaver, O., Perlingeiro, R. C., and Kyba, M. (2008b). 
 Prospective isolation of skeletal muscle stem cells with a Pax7 reporter. Stem Cells 26, 3194-
 204. 
Perez-Ruiz, A., Ono, Y., Gnocchi, V. F., and Zammit, P. S. (2008). b-catenin promotes self-renewal of 
 skeletal-muscle satellite cells. J Cell Sci 121, 1373-82. 
Snider, L., Asawachaicharn, A., Tyler, A. E., Geng, L. N., Petek, L. M., Maves, L., Miller, D. G.,  
Lemmers, R. J., Winokur, S. T., Tawil, R., van der Maarel, S. M., Filippova, G. N., and Tapscott, S. J. 
 (2009). RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new 
 candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet 18, 
 2414-30. 
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 The absence of the membrane stabilizing protein dystrophin characteristic of Duchenne 
muscular dystrophy increases vulnerability of muscle to contraction-induced damage. One strategy to 
prevent mechanical stress-induced damage in dystrophic muscle is to promote muscle fiber 
hypertrophy. Inhibition of activin receptor type IIB (ActRIIB) signaling induces skeletal muscle 
hypertrophy and results in increased muscle mass and strength in wild-type mice. Previous work also 
describes a functional benefit of increasing myofiber size in dystrophic muscle. To determine the 
efficacy of chronic ActRIIB inhibition in improving dystrophic muscle, 7-week old mdx mice were 
treated with vehicle or RAP-031, a fusion protein comprised of a form of the ActRIIB extracellular 
domain fused to a murine Fc, for 42 weeks. Body composition, grip strength and extensor digitorum 
longus (EDL) contraction force were assessed. Over the course of the study, RAP-031 significantly 
(p<0.001) increased lean tissue mass compared to the vehicle cohort. Grip strength, normalized for 
lean tissue mass, was 28.3% higher (p<0.01) in RAP-031 treated mice compared to the control group. 
EDL absolute twitch and tetanus contraction forces were increased 30% (p<0.01) and 42.5% (p<0.01) 
respectively in the RAP-031 group compared to controls. The forces generated during an eccentric 
contraction (ECC) protocol were significantly greater (p<0.01) in the RAP-031 treated group in 5 trials 
compared to controls and there was no significant change in the force deficits resulting from the 
lengthening contractions.  While the rate of force loss is similar, the finding that the absolute forces 
were greater throughout the ECC protocol could support a role for RAP-031 in increasing the degree of 
damage a muscle can withstand before contraction force is diminished to a critically low level. Overall, 
these data support a therapeutic benefit provided by chronic ActRIIB inhibition to dystrophic muscle.   
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 The Bristol Genetics Laboratory is one of the three (3) United Kingdom laboratories offering 
molecular diagnostic testing in FSHD, now receiving over 350 sample requests per year.  Primarily the 
testing is based on EcoRI /BlnI +/- ApoI digestion using probe p13E-11.  Supplementary testing with 
4qA and 4qB probes (HindIII) has been introduced, but only on specific request in response to our 
explanatory comments on the initial report, and has accordingly been added to approximately 5% of 
cases.  This is proving to be helpful in at least four different situations: 
 
1) Patients with clinical FSHD who have 2 shortened D4Z4 fragments 
2) Patients with clinical FSHD, and a suspected proximal deletion involving p13E11, as they have         
no shortened fragment detected with p13E-11 
3) Patients with a neuromuscular condition but an intermediate range D4Z4 fragment where the 
clinician wishes to exclude FSHD 
4) Patients where a previous NM diagnosis has been changed by finding a shortened D4Z4 
fragment, and absolute confirmation is essential for considering pre-implantation or prenatal 
genetic diagnosis.  
 
 We present here case illustrations of these, in the context of our summary service data, and 
discuss whether introduction of fuller 4q35 haplotyping, or potentially a methylation based assay such 
as chromatin immunoprecipitation analysis, should be a target for research into diagnostic 
improvement.   
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 Molecular pathophysiology of FSHD involves the heterozygous contraction of a number of 
D4Z4 sequences, 3.3-kb tandemly repeated units on chromosome 4. Molecular diagnostics of FSHD is 
an everlasting challenge due to several factors, namely: the variability of the repeat array size within a 
wide range (from 3.3 kb to more than 300 kb), the presence of a homologous repeat array on 
chromosome 10, and the existence of two haplotypes of chromosome 4, of which only one is 
potentially pathogenic. Indeed, FSHD is associated with repeat arrays with less than 10 repeats on 4qA 
chromosomes. Contractions on 4qB or 10q chromosomes are silent. Beside these general difficulties, 
specific cases may yet add to the complexity: somatic mosaicism, translocations between 4q and 10q 
chromosomes and deletions of nearby sequences are quite common events. The current diagnostics 
procedure, based on Southern blotting, is time-consuming, expensive, and may still lead to diagnostics 
errors. Therefore, there is an obvious need for a test that will allow simple and reliable diagnostics of 
FSHD.  
 We have presented last year the preliminary results of the test we are developing for the 
diagnostics of FSHD using the Molecular Combing technology. With this technology, DNA molecules 
are linearly stretched and immobilized on a glass substrate, where they can be hybridized with 
fluorescent probes. This allows high resolution (~1 kb) observation of loci up to several hundreds of 
kilobases observed molecule by molecule. Thus, mapping of even the most complex regions is 
straightforward using this technology.  
 Following the initial development, we have focused on improving the design of the test and 
adapting it to routine use in diagnostics laboratories. Indeed, the analysis of Molecular Combing results 
requires intensive fluorescence microscopy acquisition and image processing and analysis. The new 
design allows for an improved reliability, while sparing on acquisition and analysis time. Besides, 
dramatic improvement in hands-on time has been achieved thanks to thorough automation of the most 
time- and effort-consuming steps. Image acquisition is now fully automated thanks to the adaptation of 
a fluorescence scanner, in collaboration with its manufacturer. We have also developed a fully 
automated image processing and analysis software, which we are now in the process of validating. 
This will allow for simple interpretation by the clinician, with very little workload for the technical 
staff. 
 Along with these developments, we have transferred the whole test in our routine diagnostics 
laboratory, where we have been able to test its suitability in this environment. We will present practical 
considerations involved, as well as the first results obtained in this environment. We have found 
several unexpected features in the D4Z4 region, which we will present as well. Last, we will discuss 
ongoing developments and perspectives for routine use of this test in replacement of Southern blotting, 
which should prove to be a tremendous progress in simplicity, reliability, turnover time and cost. 
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 We are studying the changes in the proteome that occur in FSHD and have been using large-
format, two-dimensional gel electrophoresis in our initial studies.  We have introduced several 
modifications to published methods that improve protein solubility and recovery, minimize proteolysis, 
reduce the loss of resolution due to contaminants and cross-linking, and enhance analysis of faint 
spots.  Key modifications are: (i) the use of 7M urea + 2 M thiourea, instead of 9M urea, in preparing 
samples and gels for isoelectric focusing; (ii) the use of a strong reducing agent followed by 4-
vinylpyridine, to block sulfhydryl groups and prevent non-specific protein cross-linking; (iii) digital 
enhancement of spots that are faintly labeled with stain; (iv) large gels that enable all proteins from the 
first dimension to be resolved in the second dimension without cutting the gel, and proteins with 
molecular masses less than 30 kDa to be resolved. These changes make 2-D gel electrophoretic 
analysis of the proteome more comprehensive, reproducible and sensitive, with minimal artifacts. We 
have begun to use our improved methods to examine fresh, snap frozen, age- and sex-matched biopsies 
of deltoid and biceps muscles from patients with FSHD and from their first degree affected and 
unaffected relatives, as well as myoblast cell lines prepared from control and affected samples.   Our 
analyses reveal ~3,000 protein spots in biopsy samples.  Very few spots change significantly between 
FSHD and unaffected controls, suggesting that the levels of expression of the vast majority of proteins 
prominent in skeletal muscle are not altered by FSHD.  
  
Supported by the FSH Society, the Muscular Dystrophy Association, and the NIH (1 U54-NS063381,  
to C. Emerson) 
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 Introduction: FSHD is an autosomal dominant disease in which lower limb involvement 
always follows that of facial and shoulder muscles and represents an unequivocal index of disease 
progression and severity. However, limited data are available on the extent and severity of pelvic and 
lower limb muscle involvement. 
 Objectives: 1) To identify the pattern of muscle involvement  most frequently observed in 
FSHD. 2) To identify the distribution and severity of muscle involvement across different ages to get 
clues about the natural history of the disease. 3) To verify the correlation between MRI-derived 
indexes and clinical scores. 4) To characterize at the histopathological level the signal abnormalities in  
T2-W sequences, which can be found in the majority of muscles during the course of the  disease. 
 Methods: We studied 204 patients, mean age 44 ± 16, with a genetically confirmed diagnosis of 
FSHD (pathogenic EcoRI/BlnI-resistant fragment ranging between 10 and 40 kb). Muscle examination 
was performed on a 1.5-Tesla MR scanner, with T1-W SE images (TR/TE=500/35 msec) and T2-W 
STIR images (T1=1 50 msec). Axial slices were obtained from psoas to distal 
foot muscles and 40 muscles were evaluated on each side. Open and needle muscle biopsies were 
performed  from  muscles with normal T1-W signal and both normal and hyperintense T2-W STIR 
sequences. 
 Results: 1) Abdominal muscles, semimembranosus, biceps femoris (long head), adductor 
magnus, tibialis anterior, and soleus where more frequently and more severely affected, while  
popliteus, tibialis posterior,  ileopsoas, flexor digitorum longus were only rarely involved on T1-W 
scans. A number of  T1-W unaffected  muscles randomly present T2-W hyperintensities, which are 
usually supposed to account for muscle inflammation/oedema. 2) A correlation was found between 
both age and size of the pathogenic EcoRI/BlnI-resistant fragment and severity of muscle involvement 
assessed by clinical severity scale and MRI-derived indexes. 3) Moreover, the overall severity of 
muscle involvement significantly correlates  with the level of clinical impairment. MRI sensitivity is 
higher than physical examination in detecting the involvement of individual muscles. 4) 
Immunological characterization shows that inflammation seems to be a constant finding in T2-STIR 
positive muscles. 
 Conclusions: Muscle MRI examination is a powerful and reliable tool in the evaluation of 
FSHD patients and may be helpful in clinical trials for the disease.  
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 Objective: to demonstrate safety, feasibility and efficacy of electrostimulation training in 
facioscapulohumeral muscular dystrophy (FSHD) patients. 
 Design: non-controlled and before-after trial  
 Participants: 9 volunteer FSHD patients (3 women and 6 men; mean age 55.7±10.4 years)  
clinically characterized by shoulder girdle and quadriceps femoris muscles weakness. Interventions: 
all patients underwent five sessions per week of electrostimulation during five months consecutively. 
Each session last 23 minutes. The muscles stimulated were deltoids, trapezius and quadriceps femoris. 
 Main outcome measures: tolerance was assessed by pain and fatigue visual analog Scales 
(VAS), average length of electrostimulation sessions (ALES), average intensity of electrostimulation 
sessions (AIES) and plasma creatine kinase (CK) value. Feasibility was assessed by patients global 
participation rate to study (GPR) and individual participation rate to sessions (IPR). Efficacy was 
assessed by manual muscle testing (MMT), maximum volunteer isometric force (MVIF), Barre test, 
six minutes walking test (6MWT) and, by a subjective autoevaluation. 
 Results: Regarding tolerance: monthly averages of session pain and fatigue VAS were not  
significant ranging respectively from 0.8 to 1.7 cm and, from 1.1 to 1.7 cm, the ALES was 23 minutes 
for every month, and average CK rate tended to decrease (from 290±46 to 245±25 UI/L). In term of 
feasibility: GPR was 100% at the end of the study and MPR ranged from 77% to 89%. For efficacy, a 
significative improvement (p<0.05) was observed for: MMT of shoulder flexion, shoulder extension 
and knee extension, MVIF of shoulder flexion and abduction, and 6MWT (from 305.7±40.1 s to 
333.8±44.9 s). Barré test improved from 57.11±14.36 to 77±21.3 but not significatively.   
 Conclusions: These data suggest that electrostimulation is a safe and effective method to 
improve strength and functionality of FSHD patient muscles, in view of reducing the progression of 
the disease. A multicentric controlled study is required to confirm these conclusions.  
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 A hallmark of dystrophic muscles is their replacement by connective tissue, and muscle 
biopsies from FSHD patients often contain only a minority of bona fide muscle cells. Since the 
primary cause that leads to muscular dystrophy is a defect within myogenic cells it is important to 
study this particular cell type (and not cells of the connective tissue) to understand the myopathy.  
 We show that it is possible to establish clonal myogenic cell lines from FSHD muscle that 
mainly consists of non-myogenic cells by overexpression of cdk4 and hTERT, and a subsequent 
cloning step. These cell lines are valuable tools to reproducibly study the effect of the FSHD mutation 
within myoblasts without the confounding influence of variable amounts of contaminating connective 
tissue cells. 
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 Facioscapulohumeral muscular dystrophy (FSHD) is characterized by wide variability in 
clinical spectrum. Penetrance is considered complete by the age of 50. The FSHD molecular defect 
consists in reduced number of a 3.3 kb sequence (D4Z4) tandemly arrayed at 4q35 locus. Fewer than 9 
repeats are present in sporadic and familial FSHD patients. However, since molecular analysis has 
become a widely used tool for FSHD diagnosis, several observations have emerged to complicate the 
evaluation of FSHD patients and genotype-phenotype correlation. 
 The great variability of FSHD clinical outcome appears to be more pronounced than expected 
with the presence of non-penetrant gene carriers, compound heterozygous patients for the FSHD-sized 
alleles, FSHD subjects carrying D4Z4 alleles of 9-11 kb in size, which are also present in the normal 
population. As a result, a correlation between the number of the D4Z4 repeats with the severity of the 
disease is difficult to establish.  
 To collect clinical information suitable for statistical analysis in patients affected by FSHD a 
clinical evaluation form has been designed. The FSHD clinical form allow to obtain the functional 
evaluation of six muscle groups affected in FSHD through a questionnaire and to assign a disability 
score ranging from 0 (no signs) to 15 (wheelchair bound) (available at www.fshd.it).  
 In 2008 we established the Italian Registry for FSHD, which gathers 1037 molecularly 
diagnosed index cases. The clinical network, composed by 11 clinical centres, has collected the 
majority of the FSHD Italian family.  
 A preliminary study was conducted on 492 subjects carrying D4Z4 deleted alleles. As expected 
the FSHD score, a measure of disability, increases with age. Notably, in the group including subjects 
younger than 40 years the number of males exceeds the number of females suggesting a milder 
outcome of the disease in the latter group. Additionally, our analysis revealed that in the group of 
subject older than 70 years,  15% show no signs of FSHD. 
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  As expected, correlation between D4Z4 units number and clinical expression of the disease 
quantified by FSHD score showed that the percentage of subjects with no signs of FSHD inversely 
correlates with the D4Z4 repeat number. However, genotype-phenotype correlation conducted on 96 
FSHD families revealed that only in 26 families all the subjects carrying the D4Z4 molecular defect 
display clinical signs of FSHD. Interestingly in 9 families, with 3 or more subjects carrying FSHD-
sized alleles carriers, only the proband displays clinical signs of FSHD. 
  Analysis of haplotype variants using D4Z4 repeat length, 4qA/4qB bi-allelic polymorphism, 
SSLP centromeric to D4Z4, G/C SNP variants revealed novel haplotypes associated with the disease. 
Interestingly, we detected 4 novel SSLP alleles in our population. One novel haplotype associated with 
the disease is represented by 33qA D4Z4 allele associated with the C D4Z4 SNP variant. A second 
novel haplotype (4qA163) co- segregates with a 25 Kb D4Z4 allele and is associated with FSHD 
phenotype. In both families the disease is fully penetrant. 
  The presence of a high number of subjects carrying the D4Z4 deletion with no signs of the 
disease emphasizes the complexity of the mechanisms underlying FSHD pathophysiology. 
Identification and definition of the weight of additional factors in the development of FSHD will lay 
the basis for a more precise prognosis and future therapeutic intervention. Additionally our analysis of 
4q haplotypes in the Italian population indicates a wider genetic variability than that previously 
observed. This information is critical for genetic counselling and suggests the necessity of in-depth 
study to ascertain the prognostic role of 4q haplotypes. 
 
